Guillermo Garcia-Manero

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4134359/publications.pdf

Version: 2024-02-01

1,556	64,023	668 122	1755 212
papers	citations	h-index	g-index

1567	1567	1567	43310
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
2	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood, 2012, 120, 2454-2465.	1.4	2,458
3	Clinical Effect of Point Mutations in Myelodysplastic Syndromes. New England Journal of Medicine, 2011, 364, 2496-2506.	27.0	1,444
4	Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2â€²-deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 2004, 103, 1635-1640.	1.4	783
5	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 2007, 109, 52-57.	1.4	675
6	Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood, 2009, 114, 144-147.	1.4	661
7	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. Cancer Cell, 2012, 22, 153-166.	16.8	621
8	New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. Journal of Clinical Oncology, 2012, 30, 820-829.	1.6	584
9	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome:. Cancer, 2006, 106, 1090-1098.	4.1	550
10	CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	5.5	526
11	Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood, 2004, 103, 4396-4407.	1.4	522
12	Chemoimmunotherapy with hyperâ€CVAD plus rituximab for the treatment of adult Burkitt and Burkittâ€type lymphoma or acute lymphoblastic leukemia. Cancer, 2006, 106, 1569-1580.	4.1	503
13	Phase 1/2 study of the combination of 5-aza-2â€²-deoxycytidine with valproic acid in patients with leukemia. Blood, 2006, 108, 3271-3279.	1.4	492
14	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood, 2014, 124, 2705-2712.	1.4	486
15	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer, 2008, 113, 1351-1361.	4.1	458
16	Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 142	1.4	440
17	Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2012, 30, 3376-3382.	1.6	419
18	Maintenance therapy with lowâ€dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome. Cancer, 2010, 116, 5420-5431.	4.1	393

#	Article	IF	Citations
19	Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood, 2007, 110, 2302-2308.	1.4	391
20	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discovery, 2019, 9, 370-383.	9.4	380
21	Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3â€² Splice Site Selection through Use of a Different Branch Point. Cell Reports, 2015, 13, 1033-1045.	6.4	377
22	Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood, 2006, 107, 3469-3473.	1.4	371
23	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosomeâ€“positive chronic phase chronic myeloid leukemia. Blood, 2004, 103, 2873-2878.	1.4	369
24	Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosomeâ€“Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3880-3889.	1.6	361
25	Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. Journal of Clinical Oncology, 2009, 27, 504-510.	1.6	355
26	Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation. Science, 2012, 337, 1541-1546.	12.6	355
27	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood, 2013, 121, 4655-4662.	1.4	355
28	Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 1856-1862.	1.6	347
29	Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood, 2010, 116, 4422-4429.	1.4	336
30	Clinical experience with the <scp>BCL</scp>2â€inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. American Journal of Hematology, 2018, 93, 401-407.	4.1	336
31	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 382, 140-151.	27.0	335
32	A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms. Nature Genetics, 2009, 41, 455-459.	21.4	322
33	Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial. Journal of Clinical Oncology, 2009, 27, 3842-3848.	1.6	321
34	A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies. Clinical Cancer Research, 2006, 12, 4628-4635.	7.0	320
35	First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosomeâ€“positive (Ph+) acute lymphoblastic leukemia. Blood, 2010, 116, 2070-2077.	1.4	319
36	Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood, 2003, 102, 2379-2386.	1.4	313

#	Article	IF	Citations
37	The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood, 2018, 131, 2661-2669.	1.4	313
38	Acute myeloid leukemia: current progress and future directions. Blood Cancer Journal, 2021, 11, 41.	6.2	313
39	Point-of-care biosensor systems for cancer diagnostics/prognostics. Biosensors and Bioelectronics, 2006, 21, 1932-1942.	10.1	307
40	Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 2003, 101, 473-475.	1.4	304
41	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood, 2007, 109, 4679-4685.	1.4	303
42	Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood, 2012, 119, 1981-1987.	1.4	298
43	A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia, 2008, 22, 538-543.	7.2	296
44	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncology, The, 2017, 18, 100-111.	10.7	296
45	Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate. Journal of Clinical Oncology, 2005, 23, 3948-3956.	1.6	290
46	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood, 2017, 129, 572-581.	1.4	285
47	Imatinib mesylate (STI571) therapy for Philadelphia chromosomeâ€“positive chronic myelogenous leukemia in blast phase. Blood, 2002, 99, 3547-3553.	1.4	282
48	Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1584-1594.	1.6	278
49	PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell, 2018, 23, 700-713.e6.	11.1	272
50	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. Journal of Clinical Oncology, 2013, 31, 2662-2670.	1.6	265
51	K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Research, 2012, 22, 399-412.	12.0	257
52	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Journal of Hematology and Oncology, 2019, 12, 1.	17.0	257
53	Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate. Clinical Cancer Research, 2005, 11, 3425-3432.	7.0	256
54	Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 60-87.	4.9	254

#	Article	IF	Citations
55	DNA Methylation Changes after 5-Aza-2â€²-Deoxycytidine Therapy in Patients with Leukemia. Cancer Research, 2006, 66, 5495-5503.	0.9	253
56	Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood, 2003, 101, 3413-3415.	1.4	247
57	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncology, The, 2015, 16, 1547-1555.	10.7	245
58	Characteristics, clinical outcome, and prognostic significance of <scp>IDH</scp> mutations in <scp>AML</scp>. American Journal of Hematology, 2015, 90, 732-736.	4.1	242
59	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer, 2010, 116, 3830-3834.	4.1	241
60	Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 2521-2527.	1.6	232
61	Results of decitabine (5â€azaâ€2â€²deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer, 2003, 98, 522-528.	4.1	230
62	Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood, 2008, 112, 981-989.	1.4	229
63	The distribution of Tâ€cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer, 2019, 125, 1470-1481.	4.1	229
64	Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood, 2003, 101, 3794-3800.	1.4	215
65	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 2017, 129, 1275-1283.	1.4	214
66	Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood, 2005, 105, 940-947.	1.4	213
67	Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 2003, 101, 1692-1697.	1.4	210
68	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood, 2010, 115, 1131-1136.	1.4	210
69	Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nature Communications, 2020, 11, 5327.	12.8	208
70	SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood, 2012, 119, 569-572.	1.4	203
71	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematology,the, 2020, 7, e724-e736.	4.6	201
72	TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer, 2016, 122, 3484-3491.	4.1	200

#	Article	IF	Citations
73	A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 2008, 112, 1638-1645.	1.4	199
74	Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias. Clinical Cancer Research, 2004, 10, 3371-3376.	7.0	195
75	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	7.2	195
76	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	1.4	195
77	Impact of complete molecular response on survival in patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia. Blood, 2016, 128, 504-507.	1.4	194
78	Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood, 2012, 120, 4840-4845.	1.4	193
79	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 240-248.	10.7	192
80	Lowâ€dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer, 2009, 115, 1899-1905.	4.1	191
81	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica, 2015, 100, 653-661.	3.5	191
82	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematology,the, 2018, 5, e618-e627.	4.6	190
83	Evolution of decitabine development. Cancer, 2008, 112, 2341-2351.	4.1	187
84	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. Cancer, 2007, 109, 1133-1137.	4.1	182
85	Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 838-874.	4.9	181
86	Longâ€term followâ€up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with <scp>P</scp>hiladelphia chromosomeâ€“positive acute lymphoblastic leukemia. Cancer, 2015, 121, 4158-4164.	4.1	181
87	Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 30-56.	4.9	177
88	Oncogenic functions of the transcription factor Nrf2. Free Radical Biology and Medicine, 2013, 65, 750-764.	2.9	176
89	Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood, 2009, 113, 6330-6337.	1.4	175
90	Result of high-dose imatinib mesylate in patients with Philadelphia chromosomeâ€”positive chronic myeloid leukemia after failure of interferon-Î±. Blood, 2003, 102, 83-86.	1.4	174

#	Article	IF	Citations
91	Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood, 2007, 109, 3214-3218.	1.4	174
92	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 2768-2778.	1.6	173
93	Antileukemia activity of the combination of 5-aza-2â€²-deoxycytidine with valproic acid. Leukemia Research, 2005, 29, 739-748.	0.8	167
94	Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia, 2018, 32, 1094-1105.	7.2	164
95	The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results. Blood, 2019, 134, 569-569.	1.4	161
96	Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Journal of Clinical Oncology, 2012, 30, 2204-2210.	1.6	158
97	DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clinical Cancer Research, 2002, 8, 2217-24.	7.0	158
98	Hyperâ€CVAD plus ponatinib versus hyperâ€CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2016, 122, 3650-3656.	4.1	156
99	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 1788-1797.	1.6	156
100	Myelodysplastic syndromes: 2018 update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2018, 93, 129-147.	4.1	154
101	Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers. Clinical Cancer Research, 2008, 14, 6296-6301.	7.0	153
102	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood, 2015, 125, 1857-1865.	1.4	153
103	Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis. Journal of Clinical Oncology, 2009, 27, 4760-4766.	1.6	152
104	Phase II Study of Dasatinib in Philadelphia Chromosomeâ€"Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis. Clinical Cancer Research, 2008, 14, 3906-3915.	7.0	151
105	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood, 2009, 113, 2154-2160.	1.4	151
106	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood, 2017, 130, 1514-1522.	1.4	151
107	Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2011, 29, 516-523.	1.6	148
108	Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncology, The, 2017, 18, 1317-1326.	10.7	148

#	Article	IF	Citations
109	Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosomeâ€“positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood, 2003, 101, 97-100.	1.4	147
110	Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2008, 26, 196-203.	1.6	145
111	Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood, 2020, 136, 674-683.	1.4	144
112	Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood, 2010, 116, 3163-3170.	1.4	143
113	Cause of death in patients with lowerâ€risk myelodysplastic syndrome. Cancer, 2010, 116, 2174-2179.	4.1	142
114	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 496-508.	10.7	142
115	Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic Syndrome. Journal of Clinical Oncology, 2004, 22, 1287-1292.	1.6	141
116	Time-dependent changes in mortality and transformation risk in MDS. Blood, 2016, 128, 902-910.	1.4	140
117	Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System. Journal of Clinical Oncology, 2011, 29, 1963-1970.	1.6	139
118	Phase I/II trial of the combination of midostaurin (PKC412) and 5â€azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. American Journal of Hematology, 2015, 90, 276-281.	4.1	139
119	Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. International Journal of Cancer, 2009, 125, 723-729.	5.1	134
120	The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood, 2011, 118, 4541-4546.	1.4	133
121	Favorable Outcome for Lymphoblastic Lymphoma (LL) After Frontline Therapy with the Hyper-CVAD Regimens: An Update.. Blood, 2009, 114, 4099-4099.	1.4	133
122	Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model. Journal of Clinical Oncology, 2011, 29, 2240-2246.	1.6	131
123	Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer, 2008, 113, 3186-3191.	4.1	129
124	Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood, 2003, 101, 4131-4136.	1.4	127
125	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 897-901.	0.4	127
126	Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer, 2003, 98, 1905-1911.	4.1	124

#	Article	IF	Citations
127	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Miniâ€“Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, 230.	7.1	124
128	Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia. Journal of Clinical Oncology, 2008, 26, 5684-5688.	1.6	123
129	Results of phase 2 randomized study of lowâ€dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer, 2015, 121, 556-561.	4.1	122
130	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Advances, 2020, 4, 5580-5588.	5.2	122
131	Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer, 2007, 109, 248-255.	4.1	121
132	The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer, 2016, 122, 2186-2196.	4.1	121
133	Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines. Clinical Cancer Research, 2007, 13, 4225-4232.	7.0	119
134	Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. American Journal of Hematology, 2020, 95, 1399-1420.	4.1	119
135	Myelodysplastic syndromes: 2014 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2014, 89, 97-108.	4.1	118
136	Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leukemia Research, 2015, 39, 348-354.	0.8	115
137	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer, 2017, 123, 4391-4402.	4.1	114
138	Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer, 2007, 109, 265-273.	4.1	113
139	Activity of the oral mitogenâ€activated protein kinase kinase inhibitor trametinib in <scp>RAS</scp>â€mutant relapsed or refractory myeloid malignancies. Cancer, 2016, 122, 1871-1879.	4.1	113
140	Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma. Clinical Cancer Research, 2004, 10, 88-95.	7.0	110
141	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer, 2003, 97, 2760-2766.	4.1	107
142	PEG-IFN-Î±-2b therapy in BCR-ABLâ€“negative myeloproliferative disorders. Cancer, 2007, 110, 2012-2018.	4.1	107
143	Treatment with FLT3 inhibitor in patients with FLT3â€mutated acute myeloid leukemia is associated with development of secondary FLT3â€“tyrosine kinase domain mutations. Cancer, 2014, 120, 2142-2149.	4.1	107
144	Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer, 2008, 112, 837-845.	4.1	106

#	Article	IF	Citations
145	c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. Clinical Cancer Research, 2017, 23, 2542-2555.	7.0	105
146	Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Advances, 2020, 4, 5681-5689.	5.2	105
147	Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer, 2010, 116, 5568-5574.	4.1	104
148	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematology,the, 2019, 6, e480-e488.	4.6	103
149	Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood, 2005, 105, 2281-2286.	1.4	102
150	Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leukemia Research, 2010, 34, 752-756.	0.8	102
151	Final results of a single institution experience with a pediatricâ€based regimen, the augmented Berlinâ€“Frankfurtâ€“MÃ¼nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyperâ€CVAD regimen. American Journal of Hematology, 2016, 91, 819-823.	4.1	102
152	Minimal residual disease assessed by multiâ€parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 172, 392-400.	2.5	102
153	Myelodysplastic syndromes: 2015 Update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2015, 90, 831-841.	4.1	101
154	TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. Journal of Hematology and Oncology, 2015, 8, 45.	17.0	101
155	Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics, 2010, 5, 499-508.	2.7	100
156	Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opinion on Investigational Drugs, 2011, 20, 823-829.	4.1	98
157	An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica, 2015, 100, 1117-1130.	3.5	97
158	An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematology,the, 2019, 6, e194-e203.	4.6	97
159	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 2021, 35, 3542-3550.	7.2	97
160	Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clinical Cancer Research, 2002, 8, 2177-87.	7.0	97
161	Demethylating agents in myeloid malignancies. Current Opinion in Oncology, 2008, 20, 705-710.	2.4	96
162	Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound Î²-phenylethyl isothiocyanate. Blood, 2010, 116, 2732-2741.	1.4	96

#	Article	IF	Citations
163	Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2013, 31, 2548-2553.	1.6	96
164	Phase II study of SU5416â€"a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitorâ€"in patients with refractory myeloproliferative diseases. Cancer, 2003, 97, 1920-1928.	4.1	95
165	Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematology,the, 2018, 5, e63-e72.	4.6	95
166	Sorafenib Combined with 5â€azacytidine in Older Patients with Untreated FLT3â€ITD Mutated Acute Myeloid Leukemia. American Journal of Hematology, 2018, 93, 1136-1141.	4.1	95
167	Histone Deacetylase Inhibitors: A Review of Their Clinical Status as Antineoplastic Agents. Cancer Investigation, 2005, 23, 635-642.	1.3	94
168	Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood, 2010, 116, 5818-5823.	1.4	93
169	Outcome of patients with lowâ€risk and intermediateâ€1â€risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium. Cancer, 2015, 121, 876-882.	4.1	93
170	Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nature Immunology, 2020, 21, 535-545.	14.5	92
171	Augmented Berlinâ€Frankfurtâ€MÃ¼nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer, 2014, 120, 3660-3668.	4.1	91
172	The emerging role of immune checkpoint based approaches in AML and MDS. Leukemia and Lymphoma, 2018, 59, 790-802.	1.3	90
173	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 3737-3746.	1.6	90
174	Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosomeâ€positive chronic myelogenous leukemia in the chronic phase. Cancer, 2003, 98, 2636-2642.	4.1	89
175	Phase I and pharmacodynamic study of TriapineÂ®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leukemia Research, 2003, 27, 1077-1083.	0.8	89
176	Acute Myeloid Leukemia and Myelodysplastic Syndromes After Radiation Therapy Are Similar to De Novo Disease and Differ From Other Therapy-Related Myeloid Neoplasms. Journal of Clinical Oncology, 2012, 30, 2340-2347.	1.6	89
177	Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. British Journal of Haematology, 2004, 125, 187-195.	2.5	88
178	Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood, 2011, 118, 4690-4693.	1.4	88
179	Malignancyâ€associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer, 2016, 122, 2857-2866.	4.1	88
180	Phase 2, randomized, doubleâ€blind study of pracinostat in combination with azacitidine in patients with untreated, higherâ€risk myelodysplastic syndromes. Cancer, 2017, 123, 994-1002.	4.1	88

#	Article	IF	Citations
181	Chemoimmunotherapy with inotuzumab ozogamicin combined with miniâ€hyperâ€CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia in first salvage. Cancer, 2018, 124, 4044-4055.	4.1	88
182	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Advances, 2019, 3, 851-861.	5.2	88
183	Adaptive Randomized Study of Idarubicin and Cytarabine Versus Troxacitabine and Cytarabine Versus Troxacitabine and Idarubicin in Untreated Patients 50 Years or Older With Adverse Karyotype Acute Myeloid Leukemia. Journal of Clinical Oncology, 2003, 21, 1722-1727.	1.6	86
184	DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and highâ€risk disease. American Journal of Hematology, 2019, 94, 757-766.	4.1	86
185	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Advances, 2020, 4, 482-495.	5.2	86
186	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget, 2016, 7, 14172-14187.	1.8	86
187	Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer, 2006, 106, 120-127.	4.1	85
188	Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. Cancer Cell, 2015, 27, 644-657.	16.8	85
189	Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nature Immunology, 2017, 18, 236-245.	14.5	85
190	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	1.4	85
191	Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer, 2003, 98, 437-457.	4.1	84
192	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer, 2008, 113, 1933-1952.	4.1	84
193	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Advances, 2019, 3, 922-933.	5.2	84
194	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematology,the, 2019, 6, e29-e37.	4.6	84
195	Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clinical Cancer Research, 2002, 8, 2167-76.	7.0	84
196	Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood, 2006, 107, 880-884.	1.4	83
197	Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood, 2006, 108, 1174-1182.	1.4	83
198	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Advances, 2017, 1, 1312-1323.	5.2	83

#	Article	IF	Citations
199	FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. American Journal of Hematology, 2013, 88, 56-59.	4.1	82
200	Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies. Clinical Cancer Research, 2005, 11, 6615-6624.	7.0	81
201	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematology,the, 2021, 8, e552-e561.	4.6	81
202	Hypermethylation and Silencing of the Putative Tumor Suppressor Tazarotene-Induced Gene 1 in Human Cancers. Cancer Research, 2004, 64, 2411-2417.	0.9	80
203	Epigenetics of Acute Lymphocytic Leukemia. Seminars in Hematology, 2009, 46, 24-32.	3.4	80
204	Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica, 2021, 106, 894-898.	3.5	80
205	Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nature Communications, 2018, 9, 2670.	12.8	79
206	Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1â€“Risk Myelodysplastic Syndromes. Annals of Internal Medicine, 2020, 172, 513.	3.9	78
207	Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. American Journal of Hematology, 1999, 60, 130-135.	4.1	77
208	Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood, 2010, 115, 2412-2419.	1.4	77
209	Therapy with azanucleosides for myelodysplastic syndromes. Nature Reviews Clinical Oncology, 2010, 7, 433-444.	27.6	76
210	A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leukemia and Lymphoma, 2013, 54, 321-328.	1.3	76
211	Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Research, 2003, 27, 893-897.	0.8	74
212	A pilot pharmacokinetic study of oral azacitidine. Leukemia, 2008, 22, 1680-1684.	7.2	74
213	Hyperâ€CVAD plus nelarabine in newly diagnosed adult Tâ€cell acute lymphoblastic leukemia and Tâ€lymphoblastic lymphoma. American Journal of Hematology, 2018, 93, 91-99.	4.1	74
214	Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory Leukemia. Journal of Clinical Oncology, 2002, 20, 656-664.	1.6	73
215	RIL, a LIM Gene on 5q31, Is Silenced by Methylation in Cancer and Sensitizes Cancer Cells to Apoptosis. Cancer Research, 2007, 67, 1997-2005.	0.9	72
216	Myelodysplastic syndromes: 2012 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2012, 87, 692-701.	4.1	72

#	Article	IF	Citations
217	Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2003, 51, 87-90.	2.3	71
218	Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. Journal of Clinical Oncology, 2009, 27, 1637-1643.	1.6	71
219	Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?. Journal of Clinical Oncology, 2011, 29, 4260-4265.	1.6	71
220	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematology,the, 2019, 6, e317-e327.	4.6	71
221	Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome. Journal of Clinical Oncology, 2010, 28, 285-291.	1.6	70
222	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory <scp>B</scp>â€cell acute lymphoblastic leukemia. Cancer, 2017, 123, 294-302.	4.1	70
223	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer, 2020, 126, 765-774.	4.1	69
224	Treatment of coreâ€bindingâ€factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colonyâ€stimulating factor results in improved eventâ€free survival. Cancer, 2008, 113, 3181-3185.	4.1	68
225	Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wildâ€typeTP53. Cancer, 2012, 118, 2879-2888.	4.1	68
226	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. American Journal of Hematology, 2018, 93, 371-374.	4.1	68
227	Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer, 2003, 97, 695-702.	4.1	66
228	Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. American Journal of Hematology, 2014, 89, 813-818.	4.1	66
229	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematology,the, 2018, 5, e411-e421.	4.6	66
230	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 673-673.	1.4	66
231	Salvage Therapy for Refractory or Relapsed Acute Lymphocytic Leukemia. Hematology/Oncology Clinics of North America, 2001, 15, 163-205.	2.2	65
232	Simultaneous homoharringtonine and interferon-Î± in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer, 2002, 94, 2024-2032.	4.1	65
233	Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood, 2006, 107, 480-482.	1.4	65
234	Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica, 2013, 98, 217-221.	3.5	65

#	Article	IF	Citations
235	Clonal chromosomal abnormalities appearing in Philadelphia chromosomeâ€“negative metaphases during CML treatment. Blood, 2017, 130, 2084-2091.	1.4	65
236	Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood, 2011, 117, 1822-1827.	1.4	64
237	Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. British Journal of Haematology, 2015, 168, 646-653.	2.5	64
238	Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica, 2017, 102, 1661-1670.	3.5	64
239	Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood, 2019, 134, 570-570.	1.4	64
240	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer, 2017, 123, 426-435.	4.1	63
241	Inotuzumab ozogamicin in combination with lowâ€intensity chemotherapy (miniâ€HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2019, 125, 2579-2586.	4.1	63
242	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Frontiers in Oncology, 2021, 11, 656218.	2.8	63
243	Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation. Journal of Clinical Oncology, 2011, 29, 2507-2513.	1.6	62
244	Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAGâ€GO) as frontâ€line regimen in patients with core binding factor acute myelogenous leukemia. American Journal of Hematology, 2014, 89, 964-968.	4.1	62
245	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Advances, 2019, 3, 508-518.	5.2	62
246	Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood, 2002, 100, 1590-5.	1.4	62
247	Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer, 2005, 104, 547-554.	4.1	61
248	Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. American Journal of Hematology, 2013, 88, 1024-1029.	4.1	61
249	Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes. PLoS ONE, 2013, 8, e71120.	2.5	61
250	Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia, 2021, 35, 3282-3286.	7.2	61
251	Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nature Communications, 2021, 12, 2607.	12.8	61
252	The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy. Clinical Cancer Research, 2010, 16, 3923-3932.	7.0	60

#	Article	IF	Citations
253	Clofarabine plus lowâ€dose cytarabine followed by clofarabine plus lowâ€dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer, 2012, 118, 4471-4477.	4.1	60
254	Lack of association ofIDH1, IDH2andDNMT3Amutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leukemia and Lymphoma, 2014, 55, 1925-1929.	1.3	60
255	A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 344-344.	1.4	60
256	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study. Blood, 2021, 138, 244-244.	1.4	60
257	DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clinical Cancer Research, 2002, 8, 1897-903.	7.0	60
258	Granulocyteâ€“colonyâ€stimulating factor (filgrastim) may overcome imatinibâ€induced neutropenia in patients with chronicâ€phase chronic myelogenous leukemia. Cancer, 2004, 100, 2592-2597.	4.1	59
259	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatmentâ€related mortality. American Journal of Hematology, 2021, 96, 282-291.	4.1	59
260	Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). Blood, 2019, 134, 676-676.	1.4	59
261	Decitabine in the treatment of myelodysplastic syndromes. Expert Review of Anticancer Therapy, 2010, 10, 9-22.	2.4	58
262	EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood, 2012, 119, 4524-4526.	1.4	58
263	Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncology, The, 2012, 13, 1096-1104.	10.7	58
264	A phase 1 doseâ€escalation study of ARRYâ€520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer, 2012, 118, 3556-3564.	4.1	58
265	Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. American Journal of Hematology, 2014, 89, 282-287.	4.1	58
266	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival forÂPatients with Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 47-53.	2.0	58
267	Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer, 2009, 115, 5490-5498.	4.1	57
268	Treating Leukemia in the Time of COVID-19. Acta Haematologica, 2021, 144, 132-145.	1.4	57
269	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 1-1.	1.4	57
270	Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-Î± Failure and in Late CML-CP, Comparison with Historical Controls. Clinical Cancer Research, 2004, 10, 68-75.	7.0	56

#	Article	IF	Citations
271	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Advances, 2021, 5, 1876-1883.	5.2	56
272	Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget, 2018, 9, 9714-9727.	1.8	56
273	THE HYPER-CVAD REGIMEN IN ADULT ACUTE LYMPHOCYTIC LEUKEMIA. Hematology/Oncology Clinics of North America, 2000, 14, 1381-1396.	2.2	55
274	Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine. Blood, 2019, 134, 846-846.	1.4	55
275	Biphenotypic acute leukaemia: a case series. British Journal of Haematology, 2007, 138, 213-216.	2.5	54
276	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. American Journal of Hematology, 2018, 93, 277-285.	4.1	54
277	MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 37-48.	1.3	54
278	Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. PLoS ONE, 2015, 10, e0135520.	2.5	54
279	The Cyclin-Dependent Kinase Inhibitor p57KIP2 Functions as a Tumor Suppressor Gene in Human Leukemia.. Blood, 2005, 106, 1604-1604.	1.4	54
280	NCCN GuidelinesÂ® Insights: Myelodysplastic Syndromes, Version 3.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 106-117.	4.9	54
281	Third-party umbilical cord bloodâ€“derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy, 2014, 16, 90-100.	0.7	53
282	Myeloid/lymphoid neoplasms withFGFR1rearrangement. Leukemia and Lymphoma, 2018, 59, 1672-1676.	1.3	53
283	Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood, 2016, 128, 763-763.	1.4	53
284	Phase I Study of BMS-214662, a Farnesyl Transferase Inhibitor in Patients With Acute Leukemias and High-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2005, 23, 2805-2812.	1.6	52
285	Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome. Journal of Clinical Oncology, 2010, 28, 2755-2760.	1.6	52
286	A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 401-410.	0.4	51
287	More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood, 2017, 129, 2584-2587.	1.4	51
288	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. American Journal of Hematology, 2020, 95, 612-622.	4.1	51

#	Article	IF	Citations
289	Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood, 2013, 122, 2807-2811.	1.4	50
290	Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 358-363.	0.4	50
291	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1and FLT3â€internal tandem duplication genotypes. Cancer, 2019, 125, 1091-1100.	4.1	50
292	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Blood Cancer Discovery, 2021, 2, 125-134.	5.0	50
293	Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leukemia Research, 2006, 30, 813-822.	0.8	49
294	Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 3173-3178.	1.6	49
295	Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to highâ€dose cytarabineâ€based induction chemotherapy. American Journal of Hematology, 2014, 89, 395-398.	4.1	49
296	Prognostic impact of pretreatment cytogenetics in adult <scp>P</scp>hiladelphia chromosomeâ€“negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer, 2017, 123, 459-467.	4.1	49
297	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1426-1436.	1.6	49
298	<scp>RUNX</scp>3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. British Journal of Haematology, 2015, 169, 344-351.	2.5	48
299	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research, 2015, 39, 1367-1374.	0.8	48
300	Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 1392-1397.	1.3	48
301	A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 465-465.	1.4	48
302	A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia. Clinical Cancer Research, 2004, 10, 2908-2917.	7.0	47
303	Management of patients with systemic mastocytosis: Review of M. D. Anderson Cancer Center experience. American Journal of Hematology, 2004, 77, 209-214.	4.1	47
304	EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. Neuro-Oncology, 2012, 14, 1125-1135.	1.2	47
305	Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with highâ€dose cytarabine and idarubicin. Cancer, 2012, 118, 2665-2673.	4.1	47
306	Is acute myeloid leukemia a liquid tumor?. International Journal of Cancer, 2013, 133, 534-543.	5.1	47

#	Article	IF	Citations
307	A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes. Clinical Cancer Research, 2015, 21, 985-994.	7.0	47
308	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer, 2017, 123, 3050-3060.	4.1	47
309	Myelodysplastic syndromes: 2011 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2011, 86, 490-498.	4.1	46
310	Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia. Cancer, 2011, 117, 572-580.	4.1	46
311	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients â‰¥60 years with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2013, 88, 961-966.	4.1	46
312	Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemotherapy and Pharmacology, 2014, 73, 495-501.	2.3	46
313	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (<scp>AML</scp>) and myelodysplastic syndrome (<scp>MDS</scp>). American Journal of Hematology, 2016, 91, 227-232.	4.1	46
314	Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 2018, 132, 3091-3091.	1.4	46
315	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome. Blood, 2019, 134, 565-565.	1.4	46
316	Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment. Blood, 2016, 128, 345-345.	1.4	46
317	Protein Expression of a Triad of Frequently Methylated Genes, p73, p57Kip2, and p15, Has Prognostic Value in Adult Acute Lymphocytic Leukemia Independently of Its Methylation Status. Journal of Clinical Oncology, 2005, 23, 3932-3939.	1.6	45
318	A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leukemia and Lymphoma, 2007, 48, 283-289.	1.3	45
319	Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer, 2009, 115, 4737-4744.	4.1	45
320	Epigenetic therapy of leukemia: An update. International Journal of Biochemistry and Cell Biology, 2009, 41, 72-80.	2.8	45
321	Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer, 2017, 123, 4851-4859.	4.1	45
322	Colocalization of Tissue Transglutaminase and Stress Fibers in Human Vascular Smooth Muscle Cells and Human Umbilical Vein Endothelial Cells. Experimental Cell Research, 1997, 231, 38-49.	2.6	44
323	Epigenetic Inactivation of Notch-Hes Pathway in Human B-Cell Acute Lymphoblastic Leukemia. PLoS ONE, 2013, 8, e61807.	2.5	44
324	Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up. Leukemia Research, 2015, 39, 520-524.	0.8	44

#	Article	IF	Citations
325	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nature Communications, 2021, 12, 6071.	12.8	44
326	Analysis of Aurora kinase A expression in CD34+ blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. Journal of Hematopathology, 2009, 2, 2-8.	0.4	43
327	Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients. Leukemia and Lymphoma, 2010, 51, 598-605.	1.3	43
328	Acquisition of cytogenetic abnormalities in patients with IPSS defined lowerâ€risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. American Journal of Hematology, 2013, 88, 831-837.	4.1	43
329	<scp>TP</scp>53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. British Journal of Haematology, 2015, 171, 91-99.	2.5	43
330	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e523-e533.	4.6	43
331	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-NaÃ¯ve Patients with Higher-Risk Myelodysplastic Syndrome. Blood, 2019, 134, 568-568.	1.4	43
332	Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematology,the, 2018, 5, e136-e146.	4.6	42
333	Outcome of Tâ€cell acute lymphoblastic leukemia/lymphoma: Focus on <scp>nearâ€ETP</scp> phenotype and differential impact of nelarabine. American Journal of Hematology, 2021, 96, 589-598.	4.1	42
334	A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition. Blood, 2015, 126, 2547-2547.	1.4	42
335	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). Blood, 2016, 128, 901-901.	1.4	42
336	Overexpression of miR-125a in Myelodysplastic Syndrome CD34+ Cells Modulates NF-ÎºB Activation and Enhances Erythroid Differentiation Arrest. PLoS ONE, 2014, 9, e93404.	2.5	42
337	Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget, 2016, 7, 14251-14258.	1.8	42
338	Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer, 2004, 100, 581-589.	4.1	41
339	Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leukemia Research, 2014, 38, 149-154.	0.8	41
340	Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years. Leukemia Research, 2017, 56, 88-95.	0.8	41
341	Poor outcomes associated with +der(22)t(9;22) and â^'9/9p in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. American Journal of Hematology, 2017, 92, 238-243.	4.1	41
342	Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American Journal of Hematology, 2017, 92, 7-11.	4.1	41

#	Article	IF	Citations
343	Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. Blood, 2021, 138, 371-371.	1.4	41
344	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2022, 40, 3848-3857.	1.6	41
345	Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer, 2007, 110, 2000-2006.	4.1	40
346	The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities. Cancer, 2009, 115, 5202-5209.	4.1	40
347	A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. British Journal of Haematology, 2010, 150, 72-82.	2.5	40
348	Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatric Blood and Cancer, 2012, 58, 682-689.	1.5	40
349	Myelodysplastic Syndromes, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 261-272.	4.9	40
350	Final results of a phase 2 trial of clofarabine and lowâ€dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer, 2015, 121, 2375-2382.	4.1	40
351	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 2018, 131, 1820-1832.	1.4	40
352	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. American Journal of Hematology, 2018, 93, 84-90.	4.1	40
353	Mutational landscape of myelodysplastic/myeloproliferative neoplasmâ€“unclassifiable. Blood, 2018, 132, 2100-2103.	1.4	40
354	Outcomes in patients with newly diagnosed TP53â€mutated acute myeloid leukemia with or without venetoclaxâ€based therapy. Cancer, 2021, 127, 3541-3551.	4.1	40
355	HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid Leukemia Cells via Activation of miR-19a and/or b. PLoS ONE, 2013, 8, e83018.	2.5	40
356	Improving the detection of patients with inherited predispositions to hematologic malignancies using nextâ€generation sequencingâ€based leukemia prognostication panels. Cancer, 2018, 124, 2704-2713.	4.1	39
357	The role of TGFÎ² in hematopoiesis and myeloid disorders. Leukemia, 2019, 33, 1076-1089.	7.2	39
358	Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias. Journal of Clinical Oncology, 2003, 21, 1050-1056.	1.6	38
359	Predicting survival of patients with hypocellular myelodysplastic syndrome. Cancer, 2012, 118, 4462-4470.	4.1	38
360	De novo acute myeloid leukemia risk factors. Cancer, 2012, 118, 4589-4596.	4.1	38

#	Article	IF	Citations
361	Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience. American Journal of Hematology, 2015, 90, 27-30.	4.1	38
362	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. American Journal of Hematology, 2017, 92, 599-606.	4.1	38
363	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3â€internal tandem duplication mutationâ€“positive acute myeloid leukemia. Cancer, 2019, 125, 3755-3766.	4.1	38
364	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. Blood, 2019, 134, 830-830.	1.4	38
365	HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Modern Pathology, 2007, 20, 54-62.	5.5	37
366	Clinical impact of dose reductions and interruptions of secondâ€generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. British Journal of Haematology, 2010, 150, 303-312.	2.5	37
367	Safety and clinical activity of 5â€azaâ€2â€²â€deoxycytidine (decitabine) with or without Hyperâ€<scp>CVAD</scp> in relapsed/refractory acute lymphocytic leukaemia. British Journal of Haematology, 2014, 167, 356-365.	2.5	37
368	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer, 2017, 123, 4430-4439.	4.1	37
369	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia, 2020, 34, 2489-2492.	7.2	37
370	The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia, 2021, 35, 691-700.	7.2	37
371	Acute Myeloid Leukemia With t(9;11)(p21â€“22;q23). American Journal of Clinical Pathology, 2010, 133, 686-693.	0.7	36
372	A phase 1â€2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and highâ€risk myelodysplastic syndrome. Cancer, 2011, 117, 1236-1244.	4.1	36
373	Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer, 2012, 118, 5550-5559.	4.1	36
374	Final results of the phase <scp>II</scp> study of rabbit antiâ€thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colonyâ€stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. British Journal of Haematology, 2012, 157, 312-320.	2.5	36
375	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncology, 2016, 12, 293-302.	2.4	36
376	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica, 2016, 101, e224-e227.	3.5	36
377	Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. American Journal of Hematology, 2017, 92, 845-850.	4.1	36
378	The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia. Blood, 2014, 124, 387-387.	1.4	36

#	Article	IF	Citations
379	Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leukemia and Lymphoma, 2014, 55, 2879-2886.	1.3	35
380	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a <scp>CD</scp>22 monoclonal antibody. American Journal of Hematology, 2015, 90, 193-196.	4.1	35
381	Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Advances, 2021, 5, 2173-2183.	5.2	35
382	Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2900-2900.	1.4	35
383	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood, 2017, 130, 723-723.	1.4	35
384	Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia. Clinical Cancer Research, 2005, 11, 7817-7824.	7.0	34
385	Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 244-251.	0.4	34
386	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Advances, 2018, 2, 1807-1816.	5.2	34
387	Prognosis of patients with intermediate risk IPSSâ€R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSSâ€R. American Journal of Hematology, 2018, 93, 1245-1253.	4.1	34
388	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica, 2021, 106, 2121-2130.	3.5	34
389	A phase 1b/2 study of azacitidine with PDâ€Ł1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer, 2021, 127, 3761-3771.	4.1	34
390	Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2019, 134, 283-283.	1.4	34
391	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications, 2022, 13, 1970.	12.8	34
392	Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer, 2014, 120, 1670-1676.	4.1	33
393	Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation. Cancer Letters, 2016, 377, 149-157.	7.2	33
394	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer, 2020, 126, 2193-2205.	4.1	33
395	Prognostic factors for progression in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer, 2021, 127, 2648-2656.	4.1	33
396	A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. Blood, 2021, 138, 696-696.	1.4	33

#	Article	IF	Citations
397	<scp>Treatmentâ€free</scp> remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. American Journal of Hematology, 2022, 97, 856-864.	4.1	33
398	Hypomethylating agent and venetoclax with FLT3 inhibitor â€œtripletâ€•therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer Journal, 2022, 12, 77.	6.2	33
399	Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leukemia Research, 2004, 28, 991-994.	0.8	32
400	Outcome of therapyâ€related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer, 2011, 117, 110-115.	4.1	32
401	Very longâ€term followâ€up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer, 2012, 118, 3116-3122.	4.1	32
402	Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leukemia Research, 2013, 37, 1461-1467.	0.8	32
403	Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Oncologist, 2015, 20, 1404-1412.	3.7	32
404	Outcomes of adults with relapsed or refractory Burkitt and highâ€grade Bâ€cell leukemia/lymphoma. American Journal of Hematology, 2017, 92, E114-E117.	4.1	32
405	<scp>S</scp>ignificance of recurrence of minimal residual disease detected by multiâ€parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. American Journal of Hematology, 2017, 92, 279-285.	4.1	32
406	Prognostic significance of baseline FLT3â€ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. American Journal of Hematology, 2019, 94, 984-991.	4.1	32
407	Fatigue, symptom burden, and healthâ€related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. Cancer Medicine, 2019, 8, 543-553.	2.8	32
408	Phase II study of azacitidine with pembrolizumab in patients with intermediateâ€1 or higherâ€risk myelodysplastic syndrome. British Journal of Haematology, 2021, 195, 378-387.	2.5	32
409	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer Journal, 2021, 11, 162.	6.2	32
410	MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. ELife, 2013, 2, e00825.	6.0	32
411	Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemotherapy and Pharmacology, 2003, 52, 449-452.	2.3	31
412	Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusionâ€“dependent anemia and thrombocytopenia. BMC Hematology, 2016, 16, 12.	2.6	31
413	Phase 2 study of lowâ€dose clofarabine plus cytarabine for patients with higherâ€risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer, 2017, 123, 629-637.	4.1	31
414	Venetoclax combined with <scp>FLAGâ€IDA</scp> induction and consolidation in newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2022, 97, 1035-1043.	4.1	31

#	Article	IF	Citations
415	The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opinion on Pharmacotherapy, 2007, 8, 65-73.	1.8	30
416	Potential cure of acute myeloid leukemia. Cancer, 2007, 110, 2756-2760.	4.1	30
417	Prediction model for mortality after intracranial hemorrhage in patients with leukemia. American Journal of Hematology, 2011, 86, 546-549.	4.1	30
418	Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. Leukemia Research, 2012, 36, 974-981.	0.8	30
419	Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. American Journal of Hematology, 2013, 88, 365-369.	4.1	30
420	BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wildâ€type RAS. American Journal of Hematology, 2014, 89, 499-504.	4.1	30
421	Impact of comorbidities by ACEâ€27 in the revisedâ€IPSS for patients with myelodysplastic syndromes. American Journal of Hematology, 2014, 89, 509-516.	4.1	30
422	Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. European Journal of Haematology, 2015, 95, 168-176.	2.2	30
423	Focal Adhesion Kinase as a Potential Target in AML and MDS. Molecular Cancer Therapeutics, 2017, 16, 1133-1144.	4.1	30
424	Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Advances, 2017, 1, 1031-1036.	5.2	30
425	A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 658-663.e2.	0.4	30
426	Characteristics of pericardial effusions in patients with leukemia. Cancer, 2010, 116, 2366-2371.	4.1	29
427	Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Design, Development and Therapy, 2010, 4, 221.	4.3	29
428	Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. American Journal of Surgical Pathology, 2018, 42, 799-806.	3.7	29
429	KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Advances, 2018, 2, 2491-2504.	5.2	29
430	Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. American Journal of Hematology, 2020, 95, 227-229.	4.1	29
431	Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Blood, 2018, 132, 971-971.	1.4	29
432	DNA methylation in haematological malignancies: the role of decitabine. Expert Opinion on Investigational Drugs, 2003, 12, 1985-1993.	4.1	28

#	Article	IF	Citations
433	The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy, 2010, 6, 976-978.	9.1	28
434	MutatedNPM1in patients with acute myeloid leukemia in remission and relapse. Leukemia and Lymphoma, 2014, 55, 1337-1344.	1.3	28
435	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Modern Pathology, 2015, 28, 373-382.	5.5	28
436	KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood, 2016, 128, 2819-2823.	1.4	28
437	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. American Journal of Hematology, 2020, 95, 1288-1295.	4.1	28
438	Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRÎ± mutation status. Leukemia Research, 2009, 33, 837-839.	0.8	27
439	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. American Journal of Hematology, 2015, 90, 769-773.	4.1	27
440	Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leukemia Research, 2016, 41, 43-47.	0.8	27
441	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. Journal of Cutaneous Pathology, 2017, 44, 1075-1079.	1.3	27
442	Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer, 2018, 124, 4192-4201.	4.1	27
443	A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline secondâ€•and thirdâ€generation tyrosine kinase inhibitors. Cancer Medicine, 2018, 7, 5457-5469.	2.8	27
444	Relapse and death during first remission in acute myeloid leukemia. Haematologica, 2008, 93, 633-634.	3.5	26
445	Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Leukemia Research, 2010, 34, 221-228.	0.8	26
446	A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higherâ€risk myelodysplastic syndrome. Cancer, 2012, 118, 722-728.	4.1	26
447	Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. British Journal of Haematology, 2014, 166, 646-659.	2.5	26
448	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia, 2018, 32, 2512-2518.	7.2	26
449	Philadelphia chromosomeâ€positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. American Journal of Hematology, 2019, 94, 1388-1395.	4.1	26
450	Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study. Blood, 2018, 132, 234-234.	1.4	26

#	Article	IF	Citations
451	Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). Blood, 2019, 134, 678-678.	1.4	26
452	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 2022, 28, 557-567.	30.7	26
453	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematology,the, 2022, 9, e350-e360.	4.6	26
454	Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leukemia Research, 2008, 32, 1505-1509.	0.8	25
455	Modeling interactions between leukemiaâ€specific chromosomal changes, somatic mutations, and gene expression patterns during progression of coreâ€binding factor leukemias. Genes Chromosomes and Cancer, 2010, 49, 182-191.	2.8	25
456	Prognosis of Myelodysplastic Syndromes. Hematology American Society of Hematology Education Program, 2010, 2010, 330-337.	2.5	25
457	Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. American Journal of Hematology, 2012, 87, 127-129.	4.1	25
458	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. International Journal of Hematology, 2019, 109, 545-552.	1.6	25
459	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphiaâ€negative Bâ€cell acute lymphoblastic leukemia is a strong predictor for survival. American Journal of Hematology, 2020, 95, 144-150.	4.1	25
460	Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica, 2020, 105, 1567-1574.	3.5	25
461	Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).. Blood, 2007, 110, 29-29.	1.4	25
462	Prediction of early (4â€week) mortality in acute myeloid leukemia with intensive chemotherapy. American Journal of Hematology, 2022, 97, 68-78.	4.1	25
463	Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. British Journal of Haematology, 2006, 134, 58-60.	2.5	24
464	Residual DNA methylation at remission is prognostic in adult Philadelphia chromosomeâ€“negative acute lymphocytic leukemia. Blood, 2009, 113, 1892-1898.	1.4	24
465	Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood, 2009, 113, 5058-5063.	1.4	24
466	Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematology,the, 2015, 2, e12-e20.	4.6	24
467	Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-transretinoic acid plus chemotherapy or with all-transretinoic acid plus arsenic trioxide. Leukemia and Lymphoma, 2015, 56, 1342-1345.	1.3	24
468	An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. American Journal of Hematology, 2017, 92, 674-682.	4.1	24

#	Article	IF	Citations
469	Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Medicine, 2019, 8, 6559-6565.	2.8	24
470	Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification. Theranostics, 2019, 9, 3768-3779.	10.0	24
471	Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Advances, 2020, 4, 1670-1677.	5.2	24
472	Validation of International Working Group response criteria in higherâ€risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. Cancer Medicine, 2021, 10, 447-453.	2.8	24
473	Longâ€term followâ€up of salvage therapy using a combination of inotuzumab ozogamicin and miniâ€“hyperâ€CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. Cancer, 2021, 127, 2025-2038.	4.1	24
474	Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer Journal, 2021, 11, 98.	6.2	24
475	Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Advances, 2021, 5, 5415-5419.	5.2	24
476	A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood, 2018, 132, 798-798.	1.4	24
477	Lack of p21CIP1 DNA methylation in acute lymphocytic leukemia. Blood, 2002, 100, 3432-3433.	1.4	23
478	Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biology of Blood and Marrow Transplantation, 2013, 19, 214-220.	2.0	23
479	Comparing the prognostic value of risk stratifying models for patients with lowerâ€risk myelodysplastic syndromes: Is one model better?. American Journal of Hematology, 2015, 90, 1036-1040.	4.1	23
480	Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*. Leukemia and Lymphoma, 2017, 58, 1325-1331.	1.3	23
481	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer, 2018, 124, 2534-2540.	4.1	23
482	Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. Modern Pathology, 2018, 31, 1141-1154.	5.5	23
483	Prediction for sustained deep molecular response of BCRâ€ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer, 2018, 124, 1160-1168.	4.1	23
484	First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). Blood, 2013, 122, 497-497.	1.4	23
485	An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. Blood, 2014, 124, 3251-3251.	1.4	23
486	Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms. Blood, 2016, 128, 1940-1940.	1.4	23

#	Article	IF	Citations
487	Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML).. Blood, 2006, 108, 2655-2655.	1.4	23
488	Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clinical Cancer Research, 2002, 8, 2134-41.	7.0	23
489	Significance of Thrombocytopenia in Myelodysplastic Syndromes: Associations and Prognostic Implications. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 237-241.	0.4	22
490	The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Annals of Hematology, 2013, 92, 1335-1343.	1.8	22
491	Chronic myelomonocytic leukemia: Forefront of the field in 2015. Critical Reviews in Oncology/Hematology, 2015, 95, 222-242.	4.4	22
492	Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. Current Opinion in Hematology, 2018, 25, 146-153.	2.5	22
493	Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia, 2020, 34, 872-881.	7.2	22
494	Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agent 5-aza-2â€²-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia.. Blood, 2005, 106, 408-408.	1.4	22
495	A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy. Blood, 2016, 128, 227-227.	1.4	22
496	C-kit receptor expression in acute leukemiasâ€"association with patient and disease characteristics and with outcome. Leukemia Research, 2004, 28, 373-378.	0.8	21
497	Interferon Î± therapy for patients with essential thrombocythemia. Cancer, 2005, 103, 2551-2557.	4.1	21
498	Future Directions for the Use of Hypomethylating Agents. Seminars in Hematology, 2005, 42, S50-S59.	3.4	21
499	Modifying the Epigenome as a Therapeutic Strategy in Myelodysplasia. Hematology American Society of Hematology Education Program, 2007, 2007, 405-411.	2.5	21
500	Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 661-672.	3.3	21
501	Phase II study of methotrexate, vincristine, pegylatedâ€asparaginase, and dexamethasone (<scp>MO</scp>p<scp>AD</scp>) in patients with relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology, 2015, 90, 120-124.	4.1	21
502	Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer, 2019, 125, 1855-1866.	4.1	21
503	Longâ€term results of frontline dasatinib in chronic myeloid leukemia. Cancer, 2020, 126, 1502-1511.	4.1	21
504	Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 905-905.	1.4	21

#	Article	IF	Citations
505	Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2019, 134, 3807-3807.	1.4	21
506	Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). Blood, 2021, 138, 246-246.	1.4	21
507	Salvage therapy using <scp>FLT</scp>3 inhibitors may improve longâ€term outcome of relapsed or refractory <scp>AML</scp> in patients with <scp>FLT</scp>3â€<scp>ITD</scp>. British Journal of Haematology, 2013, 161, 659-666.	2.5	20
508	A phase 2, randomized, doubleâ€blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System lowâ€or intermediateâ€1â€“risk myelodysplastic syndrome. American Journal of Hematology, 2014, 89, E156-62.	4.1	20
509	Analysis of class I and II histone deacetylase gene expression in human leukemia. Leukemia and Lymphoma, 2015, 56, 3426-3433.	1.3	20
510	Characterization of <scp>TP</scp>53 mutations in lowâ€grade myelodysplastic syndromes and myelodysplastic syndromes with a nonâ€complex karyotype. European Journal of Haematology, 2017, 99, 536-543.	2.2	20
511	Outcomes with lower intensity therapy inTP53-mutated acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2238-2241.	1.3	20
512	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research, 2018, 73, 51-57.	0.8	20
513	CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. Leukemia Research, 2018, 72, 79-85.	0.8	20
514	Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia, 2018, 32, 2698-2701.	7.2	20
515	SOHO State of the Art & Next Questions: Myelodysplastic Syndromes: A New Decade. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 1-16.	0.4	20
516	A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes. Blood, 2018, 132, 793-793.	1.4	20
517	Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 453-453.	1.4	20
518	Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS). Blood, 2008, 112, 635-635.	1.4	20
519	Molecular Responses Are Observed across Mutational Spectrum in Treatment-NaÃ¯ve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine. Blood, 2021, 138, 241-241.	1.4	20
520	Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-? regimens for early chronic phase. Cancer, 2003, 98, 1430-1437.	4.1	19
521	Inhibition of IGFâ€IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinibâ€resistant chronic myeloid leukaemia cells. Journal of Cellular and Molecular Medicine, 2010, 14, 1777-1792.	3.6	19
522	Levels of miRâ€29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5â€azacytidine, valproic acid, and ATRA. American Journal of Hematology, 2011, 86, 237-238.	4.1	19

#	Article	IF	Citations
523	Clonal hematopoiesis of indeterminate potentialâ€“associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer, 2019, 125, 2233-2241.	4.1	19
524	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. American Journal of Hematology, 2021, 96, 241-250.	4.1	19
525	Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia, 2022, 36, 257-262.	7.2	19
526	Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer, 2021, 127, 3552-3565.	4.1	19
527	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2018, 132, 286-286.	1.4	19
528	Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). Blood, 2019, 134, 290-290.	1.4	19
529	Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 83-83.	1.4	19
530	Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2021, 138, 2298-2298.	1.4	19
531	Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leukemia Research, 2005, 29, 881-885.	0.8	18
532	Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 163-168.e2.	0.4	18
533	TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyperâ€CVADâ€based regimens. Cancer, 2017, 123, 3717-3724.	4.1	18
534	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. Journal of Hematology and Oncology, 2020, 13, 132.	17.0	18
535	A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leukemia Research, 2021, 104, 106555.	0.8	18
536	Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.. Journal of Clinical Oncology, 2021, 39, 7001-7001.	1.6	18
537	A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. Blood, 2016, 128, 100-100.	1.4	18
538	Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica, 2002, 87, 1114-6.	3.5	18
539	Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leukemia Research, 2005, 29, 649-652.	0.8	17
540	Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy. Oncologist, 2009, 14, 489-496.	3.7	17

#	Article	IF	Citations
541	Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology, 2015, 90, 1065-1070.	4.1	17
542	Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Investigational New Drugs, 2015, 33, 870-880.	2.6	17
543	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. Cancer, 2016, 122, 3812-3820.	4.1	17
544	Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leukemia Research, 2016, 48, 1-5.	0.8	17
545	Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Current Oncology Reports, 2016, 18, 4.	4.0	17
546	Factors associated with risk of central nervous system relapse in patients with nonâ€core binding factor acute myeloid leukemia. American Journal of Hematology, 2017, 92, 924-928.	4.1	17
547	Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Advances, 2021, 5, 3163-3173.	5.2	17
548	Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial. Blood, 2018, 132, 553-553.	1.4	17
549	Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 2019, 134, 3907-3907.	1.4	17
550	Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis. Blood, 2019, 134, 555-555.	1.4	17
551	Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. Blood, 2020, 136, 18-20.	1.4	17
552	Outcome of Salvage Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Failed Imatinib after Developing BCR-ABL Kinase Mutation.. Blood, 2005, 106, 1092-1092.	1.4	17
553	Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. Blood, 2016, 128, 2744-2744.	1.4	17
554	Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. Revista Brasileira De Hematologia E Hemoterapia, 2013, 35, 126-33.	0.7	17
555	The cure of leukemia through the optimist's prism. Cancer, 2022, 128, 240-259.	4.1	17
556	Fatal Hepatic Veno-Occlusive Disease in a Phase I Study of Mylotarg and Troxatyl in Patients with Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Acta Haematologica, 2002, 108, 164-167.	1.4	16
557	Current Therapy of Chronic Myelogenous Leukemia.. Internal Medicine, 2002, 41, 254-264.	0.7	16
558	Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leukemia Research, 2009, 33, 1361-1366.	0.8	16

#	Article	IF	Citations
559	Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leukemia and Lymphoma, 2010, 51, 475-480.	1.3	16
560	Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer, 2011, 117, 5085-5093.	4.1	16
561	Myeloid neoplasms after breast cancer: â€œtherapy-relatedâ€•not an independent poor prognostic factor. Leukemia and Lymphoma, 2015, 56, 1012-1019.	1.3	16
562	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 813-820.	1.3	16
563	Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Modern Pathology, 2020, 33, 1678-1689.	5.5	16
564	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 1494-1499.	7.2	16
565	A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. Blood, 2019, 134, 176-176.	1.4	16
566	Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Blood, 2020, 136, 37-38.	1.4	16
567	A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. Blood, 2011, 118, 115-115.	1.4	16
568	Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease. Blood, 2012, 120, 677-677.	1.4	16
569	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood, 2016, 128, 1642-1642.	1.4	16
570	Therapyâ€•related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer, 2009, 115, 101-106.	4.1	15
571	Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. Leukemia Research, 2011, 35, 351-357.	0.8	15
572	Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood, 2013, 121, 4009-4011.	1.4	15
573	Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. British Journal of Haematology, 2015, 170, 590-593.	2.5	15
574	Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer Journal, 2017, 7, 644.	6.2	15
575	Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leukemia Research, 2020, 94, 106369.	0.8	15
576	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia treated with hyperâ€CVAD and dasatinib. Cancer, 2021, 127, 2641-2647.	4.1	15

#	Article	IF	Citations
577	Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to antiâ€“PD-1â€“based therapy. Blood Advances, 2021, 5, 4569-4574.	5.2	15
578	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood, 2019, 134, 2637-2637.	1.4	15
579	Results of a Phase I/II Study of the Combination of 5-aza-2â€²-Deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia.. Blood, 2004, 104, 263-263.	1.4	15
580	Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy.. Blood, 2006, 108, 518-518.	1.4	15
581	Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).. Blood, 2007, 110, 444-444.	1.4	15
582	Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.. Blood, 2007, 110, 897-897.	1.4	15
583	Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML. Blood, 2008, 112, 228-228.	1.4	15
584	Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). Blood, 2016, 128, 3105-3105.	1.4	15
585	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica, 2021, 106, 2853-2858.	3.5	15
586	Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes. Blood, 2014, 124, 3241-3241.	1.4	15
587	Hematopoiesis under telomere attrition at the single-cell resolution. Nature Communications, 2021, 12, 6850.	12.8	15
588	Improved outcomes among newly diagnosed patients with <scp>FMSâ€like tyrosine kinase 3 internal tandem duplication</scp> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. American Journal of Hematology, 2022, 97, 329-337.	4.1	15
589	Cytoprotection in Acute Myelogenous Leukemia (AML) therapy. Seminars in Oncology, 2004, 31, 67-73.	2.2	14
590	Rare Case of Septic Arthritis Caused by Candida krusei: Case Report and Literature Review: Table 1.. Journal of Rheumatology, 2012, 39, 1308-1309.	2.0	14
591	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer, 2016, 122, 3336-3343.	4.1	14
592	Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 528-532.	0.4	14
593	Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer, 2019, 125, 3219-3224.	4.1	14
594	LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leukemia and Lymphoma, 2020, 61, 1493-1499.	1.3	14

#	Article	IF	Citations
595	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. , 2021, 9, e001818.		14
596	Targeting health-related quality of life in patients with myelodysplastic syndromes â€“ Current knowledge and lessons to be learned. Blood Reviews, 2021, 50, 100851.	5.7	14
597	Longâ€term results of a phase 2 trial of nilotinib 400Âmg twice daily in newly diagnosed patients with chronicâ€phase chronic myeloid leukemia. Cancer, 2020, 126, 1448-1459.	4.1	14
598	A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2018, 132, 32-32.	1.4	14
599	LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. Blood, 2018, 132, 687-687.	1.4	14
600	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. Blood, 2019, 134, 2723-2723.	1.4	14
601	Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2801-2801.	1.4	14
602	Delayed Achievement of Molecular Responses Is Associated with Increased Risk of Progression among Patients (pts) with Chronic Myelogenous Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib (IM).. Blood, 2006, 108, 432-432.	1.4	14
603	Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).. Blood, 2009, 114, 3431-3431.	1.4	14
604	Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes. Blood, 2011, 118, 118-118.	1.4	14
605	Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP). Blood, 2011, 118, 454-454.	1.4	14
606	Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes. Blood, 2012, 120, 424-424.	1.4	14
607	Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2013, 122, 2664-2664.	1.4	14
608	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood, 2014, 124, 388-388.	1.4	14
609	Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (â‰65 yrs) with Acute Myeloid Leukemia. Blood, 2016, 128, 1639-1639.	1.4	14
610	Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML). Blood, 2021, 138, 3409-3409.	1.4	14
611	Treatment Strategies in Myelodysplastic Syndromes. Cancer Investigation, 2008, 26, 208-216.	1.3	13
612	Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). British Journal of Haematology, 2010, 148, 386-393.	2.5	13

#	Article	IF	Citations
613	Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection. Leukemia Research, 2012, 36, 1376-1379.	0.8	13
614	Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. American Journal of Hematology, 2012, 87, 317-318.	4.1	13
615	Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. American Journal of Hematology, 2013, 88, 198-200.	4.1	13
616	Down-regulation of EZH2 expression in myelodysplastic syndromes. Leukemia Research, 2016, 44, 1-7.	0.8	13
617	Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. American Journal of Hematology, 2017, 92, 351-358.	4.1	13
618	Clinical outcomes in adult patients with aplastic anemia: A single institution experience. American Journal of Hematology, 2017, 92, 1295-1302.	4.1	13
619	Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica, 2017, 102, 1709-1717.	3.5	13
620	AML-190: Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S188-S189.	0.4	13
621	Longâ€term results of lowâ€intensity chemotherapy with clofarabine or cladribine combined with lowâ€dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2021, 96, 914-924.	4.1	13
622	Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. Blood, 2018, 132, 2702-2702.	1.4	13
623	Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 1831-1831.	1.4	13
624	Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. Blood, 2018, 132, 906-906.	1.4	13
625	Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood, 2020, 136, 9-11.	1.4	13
626	Clinical Relevance of CRp in Untreated AML.. Blood, 2005, 106, 541-541.	1.4	13
627	Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. Blood, 2006, 108, 284-284.	1.4	13
628	Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2.. Blood, 2007, 110, 1939-1939.	1.4	13
629	Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine. Blood, 2008, 112, 224-224.	1.4	13
630	Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 3721-3721.	1.4	13

#	Article	IF	Citations
631	Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. Blood, 2016, 128, 4262-4262.	1.4	13
632	Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome. Blood, 2021, 138, 537-537.	1.4	13
633	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. Journal of Hematology and Oncology, 2022, 15, 12.	17.0	13
634	Treatment of Higher-Risk Myelodysplastic Syndrome. Seminars in Oncology, 2011, 38, 673-681.	2.2	12
635	Histone methylation in myelodysplastic syndromes. Epigenomics, 2011, 3, 193-205.	2.1	12
636	Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy. Best Practice and Research in Clinical Haematology, 2012, 25, 427-435.	1.7	12
637	Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer, 2016, 16, 652.	2.6	12
638	Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. American Journal of Hematology, 2016, 91, 1221-1226.	4.1	12
639	Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Annals of Hematology, 2018, 97, 1183-1191.	1.8	12
640	Survivorship in AML â€“ a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leukemia and Lymphoma, 2020, 61, 3120-3127.	1.3	12
641	Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Modern Pathology, 2021, 34, 1143-1152.	5.5	12
642	Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood, 2018, 132, 36-36.	1.4	12
643	Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood, 2019, 134, 823-823.	1.4	12
644	A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS),. Blood, 2011, 118, 3801-3801.	1.4	12
645	Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). Blood, 2014, 124, 163-163.	1.4	12
646	Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood, 2014, 124, 385-385.	1.4	12
647	Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.. Blood, 2005, 106, 1846-1846.	1.4	12
648	Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. Clinical Advances in Hematology and Oncology, 2008, 6, 1-15.	0.3	12

#	Article	IF	Citations
649	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. American Journal of Hematology, 2022, 97, 865-876.	4.1	12
650	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leukemia and Lymphoma, 2022, 63, 2161-2170.	1.3	12
651	Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leukemia Research, 2003, 27, 301-304.	0.8	11
652	The Search for Better Prognostic Models in Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2011, 6, 13-21.	2.3	11
653	Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leukemia Research, 2011, 35, 834-836.	0.8	11
654	Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines. Clinical Proteomics, 2016, 13, 14.	2.1	11
655	Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leukemia and Lymphoma, 2018, 59, 1312-1322.	1.3	11
656	A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leukemia and Lymphoma, 2019, 60, 2207-2213.	1.3	11
657	Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leukemia and Lymphoma, 2021, 62, 909-917.	1.3	11
658	Phase II study of single-agent nivolumab in patients with myelofibrosis. Annals of Hematology, 2021, 100, 2957-2960.	1.8	11
659	Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 232-232.	1.4	11
660	Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2019, 134, 2647-2647.	1.4	11
661	Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 4243-4243.	1.4	11
662	Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2019, 134, 1641-1641.	1.4	11
663	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse. Blood, 2019, 134, 3806-3806.	1.4	11
664	Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities. Blood, 2011, 118, 608-608.	1.4	11
665	Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome. Blood, 2012, 120, 3821-3821.	1.4	11
666	Results From the Dose Escalation Phase of a Randomized Phase 1â€“2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. Blood, 2012, 120, 414-414.	1.4	11

#	Article	IF	Citations
667	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes. Blood, 2015, 126, 3746-3746.	1.4	11
668	Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study. Blood, 2016, 128, 114-114.	1.4	11
669	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood, 2016, 128, 588-588.	1.4	11
670	Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2017, 130, 815-815.	1.4	11
671	Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy.. Blood, 2009, 114, 1038-1038.	1.4	11
672	Time to blur the blast boundaries. Cancer, 2022, 128, 1568-1570.	4.1	11
673	Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. American Journal of Hematology, 2023, 98, .	4.1	11
674	Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Investigational New Drugs, 2001, 19, 13-20.	2.6	10
675	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer, 2003, 97, 3010-3016.	4.1	10
676	Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leukemia Research, 2004, 28, 657-660.	0.8	10
677	Current and Future Management Options for Myelodysplastic Syndromes. Drugs, 2010, 70, 1381-1394.	10.9	10
678	Dietary Intake of Vegetables, Fruits, and Meats/Beans as Potential Risk Factors of Acute Myeloid Leukemia: A Texas Case-Control Study. Nutrition and Cancer, 2013, 65, 1132-1140.	2.0	10
679	Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. British Journal of Haematology, 2015, 169, 595-597.	2.5	10
680	Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide. Medicine (United States), 2019, 98, e14011.	1.0	10
681	A phase II study of omacetaxine mepesuccinate for patients with higherâ€risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. American Journal of Hematology, 2019, 94, 74-79.	4.1	10
682	Phase 2 study of hyperâ€CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. American Journal of Hematology, 2020, 95, 734-739.	4.1	10
683	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3 â€ITD and IDH mutations. Cancer, 2021, 127, 381-390.	4.1	10
684	Hyperâ€CVAD plus ofatumumab versus hyperâ€CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2021, 127, 3381-3389.	4.1	10

#	Article	IF	Citations
685	Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. Blood, 2018, 132, 4057-4057.	1.4	10
686	Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment NaÃ¯ve & Relapsed (Rel)/Refractory (Ref) Patients. Blood, 2018, 132, 230-230.	1.4	10
687	Dynamics of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia (CML) after Treatment with One, Two or Three Tyrosine Kinase Inhibitors (TKI).. Blood, 2006, 108, 750-750.	1.4	10
688	Eph Receptor Tyrosine Kinases and Ephrin Ligands Are Epigenetically Inactivated in Acute Lymphoblastic Leukemia and Are Potential New Tumor Suppressor Genes in Human Leukemia.. Blood, 2007, 110, 2128-2128.	1.4	10
689	Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.. Blood, 2007, 110, 3543-3543.	1.4	10
690	FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact On Survival According to FLT3 Status.. Blood, 2009, 114, 1026-1026.	1.4	10
691	Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study. Blood, 2010, 116, 603-603.	1.4	10
692	Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML). Blood, 2010, 116, 656-656.	1.4	10
693	Final Report of a Phase I Trial of Decitabine with or without hyperCVAD In Relapsed Acute Lymphocytic Leukemia (ALL). Blood, 2010, 116, 867-867.	1.4	10
694	SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. Blood, 2012, 120, 3625-3625.	1.4	10
695	Comparing The Prognostic Value Of Risk Stratifying Models For Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Is One Model Better? A Report on The Behalf of The MDS Clinical Research Consortium. Blood, 2013, 122, 1505-1505.	1.4	10
696	Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 1683-1683.	1.4	10
697	A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS). Blood, 2015, 126, 911-911.	1.4	10
698	Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 236-250.	0.4	10
699	Use of Post-Treatment Clinical Data To Predict Response to Decitabine.. Blood, 2007, 110, 1448-1448.	1.4	10
700	Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program. Blood, 2021, 138, 4669-4669.	1.4	10
701	Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study. Leukemia and Lymphoma, 2022, 63, 1660-1668.	1.3	10
702	Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Modern Pathology, 2022, 35, 1212-1219.	5.5	10

#	Article	IF	Citations
703	Current management of patients with chronic myelomonocytic leukemia. Current Opinion in Oncology, 2017, 29, 79-87.	2.4	9
704	Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 antiinflammatory activity in hematopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2311-E2319.	7.1	9
705	Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCRâ€“ABL kinase domain mutations. International Journal of Hematology, 2018, 107, 689-695.	1.6	9
706	Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leukemia Research, 2018, 73, 78-85.	0.8	9
707	Relative survival following response to 7â€‰+â€‰3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia, 2019, 33, 371-378.	7.2	9
708	A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. British Journal of Haematology, 2020, 188, 404-412.	2.5	9
709	Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics, 2021, 16, 567-576.	2.7	9
710	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (<scp>MDS/MPNâ€RSâ€T</scp>) and myelodysplastic syndrome with ring sideroblasts (<scp>MDSâ€RS</scp>). American Journal of Hematology, 2021, 96, E246-E249.	4.1	9
711	Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations. Blood, 2018, 132, 2715-2715.	1.4	9
712	Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS). Blood, 2019, 134, 567-567.	1.4	9
713	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood, 2019, 134, 645-645.	1.4	9
714	Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. Blood, 2019, 134, 4240-4240.	1.4	9
715	Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL). Blood, 2019, 134, 3810-3810.	1.4	9
716	Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).. Blood, 2006, 108, 1954-1954.	1.4	9
717	Efficacy of Nilotinib (formerly AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). Blood, 2008, 112, 446-446.	1.4	9
718	Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood, 2015, 126, 461-461.	1.4	9
719	Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2015, 126, 94-94.	1.4	9
720	ARTS, a Pro-Apoptotic Mitochondrial Septin-Like Protein That Binds to XIAP, Is Silenced in Acute Lymphoblastic and Primitive Acute Myeloblastic Leukemia Cells.. Blood, 2004, 104, 3378-3378.	1.4	9

#	Article	IF	Citations
721	Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. Blood, 2007, 110, 9-9.	1.4	9
722	Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia. Blood, 2012, 120, 1516-1516.	1.4	9
723	A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood, 2021, 138, 1239-1239.	1.4	9
724	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	5.5	9
725	Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis. Blood, 2021, 138, 144-144.	1.4	9
726	Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. American Journal of Hematology, 2022, 97, 574-582.	4.1	9
727	Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia, 2022, 36, 1253-1260.	7.2	9
728	Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia. Cancer, 2010, 116, 5272-5278.	4.1	8
729	Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 556-562.	0.4	8
730	The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leukemia and Lymphoma, 2015, 56, 390-394.	1.3	8
731	Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents. Journal of Clinical Pathology, 2016, 69, 1001-1008.	2.0	8
732	Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. Cancer, 2018, 124, 4601-4609.	4.1	8
733	Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematological Oncology, 2019, 37, 96-102.	1.7	8
734	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. Leukemia, 2019, 33, 554-558.	7.2	8
735	The clinical impact of time to response in de novo acceleratedâ€phase chronic myeloid leukemia. American Journal of Hematology, 2020, 95, 1127-1134.	4.1	8
736	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E50-E53.	4.1	8
737	Preclinical activity of FF-10501-01, a novel inosine-5â€²-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. Leukemia Research, 2017, 59, 85-92.	0.8	8
738	A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.. Blood, 2004, 104, 1011-1011.	1.4	8

#	Article	IF	Citations
739	A Randomized Trial of High-Dose (HD) Imatinib Mesylate (IM) with or without Peg-Interferon (PEG-IFN) and GM-CSF as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP).. Blood, 2005, 106, 1084-1084.	1.4	8
740	MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.. Blood, 2006, 108, 1967-1967.	1.4	8
741	Immune Modulation of Minimal Residual Disease (MRD) in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CP): A Randomized Trial of Frontline High-Dose (HS) Imatinib Mesylate (IM) with or without Pegylated-Interferon (PEG-IFN) and GM-CSF.. Blood, 2006, 108, 2207-2207.	1.4	8
742	Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2â€²-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome.. Blood, 2007, 110, 1468-1468.	1.4	8
743	A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results. Blood, 2008, 112, 5084-5084.	1.4	8
744	Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies. Blood, 2010, 116, 3292-3292.	1.4	8
745	Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine. Blood, 2010, 116, 336-336.	1.4	8
746	Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 1295-1295.	1.4	8
747	A Patient-Reported Outcome Measure for Symptoms and Symptom Burden of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2015, 126, 2094-2094.	1.4	8
748	Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF). Blood, 2016, 128, 1127-1127.	1.4	8
749	CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies. Blood, 2016, 128, 905-905.	1.4	8
750	Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): The MD Anderson Cancer Center (MDACC) Experience. Blood, 2008, 112, 3982-3982.	1.4	8
751	Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience. Blood, 2012, 120, 3783-3783.	1.4	8
752	Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3400-3400.	1.4	8
753	A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica, 2002, 87, 804-7.	3.5	8
754	Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer, 2022, 128, 2736-2745.	4.1	8
755	Improving survival in myelodysplastic syndromes. Lancet Oncology, The, 2009, 10, 200-201.	10.7	7
756	CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. Leukemia and Lymphoma, 2016, 57, 1965-1968.	1.3	7

#	Article	IF	Citations
757	Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. Leukemia and Lymphoma, 2016, 57, 812-819.	1.3	7
758	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leukemia and Lymphoma, 2020, 61, 2811-2820.	1.3	7
759	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia, 2020, 34, 2914-2924.	7.2	7
760	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 338-344.	0.4	7
761	Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. Blood, 2018, 132, 663-663.	1.4	7
762	Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. Blood, 2018, 132, 352-352.	1.4	7
763	Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 841-841.	1.4	7
764	Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood, 2019, 134, 566-566.	1.4	7
765	Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy. Blood, 2020, 136, 23-24.	1.4	7
766	PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.. Blood, 2004, 104, 1517-1517.	1.4	7
767	A Phase I Study of the Histone Deacetylase Inhibitor MGCD0103 (MG-0103) Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS).. Blood, 2005, 106, 4639-4639.	1.4	7
768	Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood, 2008, 112, 2985-2985.	1.4	7
769	Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients.. Blood, 2009, 114, 1053-1053.	1.4	7
770	Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).. Blood, 2009, 114, 1055-1055.	1.4	7
771	Clinical Development of MGCD0103, An Isotype-Selective HDAC Inhibitor: Pericarditis/Pericardial Effusion in the Context of Overall Safety and Efficacy.. Blood, 2009, 114, 4756-4756.	1.4	7
772	Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes. Blood, 2013, 122, 387-387.	1.4	7
773	Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2541-2541.	1.4	7
774	Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study. Blood, 2015, 126, 2861-2861.	1.4	7

#	Article	IF	Citations
775	CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 452-452.	1.4	7
776	Comparison of Efficacy and Safety Results in 103 Treatment-NaÃ¯ve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA). Blood, 2015, 126, 458-458.	1.4	7
777	Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC). Blood, 2015, 126, 909-909.	1.4	7
778	Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC). Blood, 2016, 128, 297-297.	1.4	7
779	Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting. Blood, 2016, 128, 3073-3073.	1.4	7
780	CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia. Blood, 2016, 128, 4047-4047.	1.4	7
781	Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. Blood, 2006, 108, 1999-1999.	1.4	7
782	Significant Clinical Activity of the Combination of 5-Azacytidine, Valproic Acid and All-Trans Retinoic (ATRA) Acid in Leukemia: Results of a Phase I/II Study.. Blood, 2006, 108, 160-160.	1.4	7
783	Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study. Blood, 2021, 138, 66-66.	1.4	7
784	Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. Blood, 2021, 138, 2349-2349.	1.4	7
785	A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-NaÃ¯ve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2021, 138, 535-535.	1.4	7
786	Empirical examination of the neutrophil criterion (›1500 Î¼lâˆ’1) currently needed to declare CR in AML. Leukemia Research, 2003, 27, 475-479.	0.8	6
787	Spontaneous Remission of Acute Myeloid Leukemia: Report of Three Cases and Review of the Literature. Clinical Leukemia, 2008, 2, 64-67.	0.2	6
788	Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome. American Journal of Hematology, 2011, 86, 950-952.	4.1	6
789	Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. Cancer Genetics, 2016, 209, 205-214.	0.4	6
790	Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and ImmuneÂCheckpoints. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S16-S25.	0.4	6
791	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia â€“ a distinct subtype with favorable prognosis. Leukemia and Lymphoma, 2021, 62, 224-228.	1.3	6
792	Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes. Frontiers in Immunology, 2021, 12, 659625.	4.8	6

#	Article	IF	Citations
793	What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. Leukemia and Lymphoma, 2021, 62, 2762-2767.	1.3	6
794	t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?. Annals of Hematology, 2020, 99, 487-500.	1.8	6
795	Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood, 2018, 132, 84-84.	1.4	6
796	Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy. Blood, 2019, 134, 1312-1312.	1.4	6
797	Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study. Blood, 2020, 136, 10-12.	1.4	6
798	Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) â‰¥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).. Blood, 2004, 104, 875-875.	1.4	6
799	High-Dose (HD) Imatinib Provides Better Responses in Patients with Untreated Early Chronic Phase (CP) CML.. Blood, 2006, 108, 2143-2143.	1.4	6
800	Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure.. Blood, 2006, 108, 2164-2164.	1.4	6
801	Multivariate Evaluation of the Prognostic and Therapeutic Relevance of Cytogenetics in a Merged European-American Cohort of 3860 Patients with MDS.. Blood, 2007, 110, 247-247.	1.4	6
802	Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure.. Blood, 2008, 112, 1659-1659.	1.4	6
803	Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS). Blood, 2008, 112, 222-222.	1.4	6
804	A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS).. Blood, 2009, 114, 119-119.	1.4	6
805	Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine.. Blood, 2009, 114, 1769-1769.	1.4	6
806	FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations. Blood, 2011, 118, 1493-1493.	1.4	6
807	24-Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower-Risk MDS Patients. Blood, 2011, 118, 2800-2800.	1.4	6
808	Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule. Blood, 2012, 120, 1337-1337.	1.4	6
809	TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. Blood, 2014, 124, 532-532.	1.4	6
810	Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). Blood, 2015, 126, 3801-3801.	1.4	6

#	Article	IF	Citations
811	Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival. Blood, 2016, 128, 1613-1613.	1.4	6
812	Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood, 2016, 128, 2783-2783.	1.4	6
813	Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2020, 38, 7539-7539.	1.6	6
814	Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leukemia and Lymphoma, 2021, 62, 1187-1194.	1.3	6
815	Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. Blood, 2021, 138, 370-370.	1.4	6
816	Use of hypomethylating agents in myelodysplastic syndromes. Clinical Advances in Hematology and Oncology, 2007, 5, 544-52.	0.3	6
817	Prognostic implications of epigenetic silencing of p15INK4B in acute promyelocytic leukemia. Leukemia, 2003, 17, 839-840.	7.2	5
818	Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. British Journal of Haematology, 2007, 138, 555-557.	2.5	5
819	Deacetylase inhibitors for the treatment of myelodysplastic syndromes. Leukemia and Lymphoma, 2015, 56, 1205-1212.	1.3	5
820	PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S67-S73.	0.4	5
821	Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica, 2016, 101, e324-e327.	3.5	5
822	Validation of the 2016 revisions to the <scp>WHO</scp> classification in lowerâ€risk myelodysplastic syndrome. American Journal of Hematology, 2017, 92, E168-E171.	4.1	5
823	Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. Leukemia and Lymphoma, 2018, 59, 2135-2143.	1.3	5
824	Phase 1/2 study of DFPâ€10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer, 2019, 125, 1665-1673.	4.1	5
825	Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the ConnectÂ®MDS/AML Disease Registry. EJHaem, 2020, 1, 58-68.	1.0	5
826	Phase 2 study of lenalidomide maintenance for patients with highâ€risk acute myeloid leukemia in remission. Cancer, 2021, 127, 1894-1900.	4.1	5
827	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer Journal, 2021, 11, 52.	6.2	5
828	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer, 2021, 127, 3113-3124.	4.1	5

#	Article	IF	Citations
829	Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 1438-1438.	1.4	5
830	Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis. Blood, 2018, 132, 5513-5513.	1.4	5
831	Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 4017-4017.	1.4	5
832	Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. Blood, 2019, 134, 1656-1656.	1.4	5
833	Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome. Blood, 2019, 134, 3016-3016.	1.4	5
834	Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma.. Blood, 2004, 104, 3297-3297.	1.4	5
835	Use of All-Transretinoic Acid (ATRA) + Arsenic Trioxide (ATO) To Eliminate or Minimize Use of Chemotherapy (CT) in Untreated Acute Promyelocytic Leukemia (APL).. Blood, 2004, 104, 393-393.	1.4	5
836	Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.. Blood, 2006, 108, 3668-3668.	1.4	5
837	Multivariate Analysis Suggests That the Prognostic Impact of Poor Cytogenetics Is Potentially Underestimated in the IPSS.. Blood, 2007, 110, 248-248.	1.4	5
838	Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline â€œTargeted Therapyâ€•. Blood, 2007, 110, 2858-2858.	1.4	5
839	A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.. Blood, 2007, 110, 298-298.	1.4	5
840	Pegylated Interferon-ALFA-2A (PEG-IFN-Î±-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV). Blood, 2008, 112, 658-658.	1.4	5
841	Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center.. Blood, 2008, 112, 925-925.	1.4	5
842	A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).. Blood, 2009, 114, 117-117.	1.4	5
843	Phase II Study of All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), with or without Gemtuzumab OzogamIcin (GO) for the Frontline Therapy of Patients with Acute Promyelocytic Leukemia (APL).. Blood, 2010, 116, 1080-1080.	1.4	5
844	Updated Results of Combination Cytokine Immunotherapy In the Treatment of Aplastic Anemia and Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 2920-2920.	1.4	5
845	Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). Blood, 2011, 118, 2613-2613.	1.4	5
846	Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples. Blood, 2011, 118, 969-969.	1.4	5

#	Article	IF	Citations
847	Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia. Blood, 2012, 120, 164-164.	1.4	5
848	Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies. Blood, 2012, 120, 3557-3557.	1.4	5
849	A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS. Blood, 2013, 122, 2698-2698.	1.4	5
850	48-Month Update On Survival and AML Transformation In a 600-Patient Registry Of Lower-Risk MDS Patients. Blood, 2013, 122, 2775-2775.	1.4	5
851	Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure. Blood, 2013, 122, 388-388.	1.4	5
852	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients (â‰¥60 years) with Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 794-794.	1.4	5
853	Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS. Blood, 2015, 126, 1663-1663.	1.4	5
854	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 609-609.	1.4	5
855	A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 910-910.	1.4	5
856	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. Blood, 2016, 128, 1166-1166.	1.4	5
857	Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study. Blood, 2016, 128, 2822-2822.	1.4	5
858	Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2016, 128, 346-346.	1.4	5
859	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. Blood, 2016, 128, 4320-4320.	1.4	5
860	Clinical Significance of Dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML). Blood, 2008, 112, 3217-3217.	1.4	5
861	Effect of Azacytidine on the Hematopoietic Stem and Progenitor Cell Compartments of MDS Mouse Models: Unveiling the Mechanisms of Remission and Relapse. Blood, 2015, 126, 2852-2852.	1.4	5
862	Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents. Blood, 2021, 138, 3677-3677.	1.4	5
863	Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML. Blood, 2021, 138, 798-798.	1.4	5
864	Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia, 2022, 36, 1189-1192.	7.2	5

#	Article	IF	Citations
865	Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia, 2022, 36, 1432-1435.	7.2	5
866	Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leukemia and Lymphoma, 2010, 51, 1478-1484.	1.3	4
867	Integrating Care for Patients With Lower Risk Myelodysplastic Syndrome. Seminars in Oncology, 2011, 38, 658-666.	2.2	4
868	Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Therapeutic Advances in Hematology, 2014, 5, 29-34.	2.5	4
869	Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to haveIDH1orIDH2mutations. Leukemia and Lymphoma, 2014, 55, 1431-1434.	1.3	4
870	Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. American Journal of Hematology, 2015, 90, E134-5.	4.1	4
871	Does the concept of lower-risk myelodysplastic syndrome need to be revisited?. Leukemia Research, 2015, 39, 1003-1005.	0.8	4
872	Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. British Journal of Haematology, 2016, 173, 161-165.	2.5	4
873	Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S9.	0.4	4
874	Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer, 2017, 123, 609-616.	4.1	4
875	Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leukemia and Lymphoma, 2017, 58, 866-871.	1.3	4
876	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. American Journal of Hematology, 2019, 94, E188-E190.	4.1	4
877	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. American Journal of Hematology, 2020, 95, E313-E315.	4.1	4
878	Clinical value of event-free survival in acute myeloid leukemia. Blood Advances, 2020, 4, 1690-1699.	5.2	4
879	Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leukemia Research, 2021, 101, 106511.	0.8	4
880	MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-NaÃ¯ve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S343.	0.4	4
881	Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2018, 132, 231-231.	1.4	4
882	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. Blood, 2018, 132, 34-34.	1.4	4

#	Article	IF	Citations
883	Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. Blood, 2018, 132, 464-464.	1.4	4
884	Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data. Blood, 2018, 132, 1801-1801.	1.4	4
885	Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies. Blood, 2018, 132, 1798-1798.	1.4	4
886	Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS). Blood, 2019, 134, 1726-1726.	1.4	4
887	Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs). Blood, 2019, 134, 458-458.	1.4	4
888	Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood, 2019, 134, 1296-1296.	1.4	4
889	The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood, 2019, 134, 1642-1642.	1.4	4
890	Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD). Blood, 2019, 134, 1299-1299.	1.4	4
891	The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. Blood, 2019, 134, 1436-1436.	1.4	4
892	Long-Term Incidence and Outcome of BCR-ABL Mutations in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate - P-Loop Mutations Are Not Associated with Worse Outcome.. Blood, 2004, 104, 1007-1007.	1.4	4
893	Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.. Blood, 2004, 104, 2956-2956.	1.4	4
894	Plausibility of Delaying Induction Therapy in Untreated AML.. Blood, 2004, 104, 879-879.	1.4	4
895	Decitabine Low-Dose Schedule (100 mg/m2/Course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.. Blood, 2005, 106, 2522-2522.	1.4	4
896	Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 2963-2963.	1.4	4
897	MK-0457 Is a Novel Aurora Kinase and Janus Kinase 2 (JAK2) Inhibitor with Activity in Transformed JAK2-Positive Myeloproliferative Disease (MPD).. Blood, 2006, 108, 4893-4893.	1.4	4
898	Outcomes of MDS Patients with Chromosome 7 Abnormalities Treated with 5-Azacytidine.. Blood, 2007, 110, 1449-1449.	1.4	4
899	Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).. Blood, 2007, 110, 1851-1851.	1.4	4
900	Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients (Pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML).. Blood, 2007, 110, 1932-1932.	1.4	4

#	Article	IF	Citations
901	Phase II Study of Dasatinib (SPRYCELâ„¢) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.. Blood, 2007, 110, 3551-3551.	1.4	4
902	Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.. Blood, 2007, 110, 441-441.	1.4	4
903	Hypomethylating Therapy for the Treatment of Acute Erythroleukemia Patients.. Blood, 2009, 114, 2069-2069.	1.4	4
904	Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Treated On Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid.. Blood, 2009, 114, 2074-2074.	1.4	4
905	Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 2079-2079.	1.4	4
906	A Prognostic Model of Therapy-Related Myelodysplastic syndrome .. Blood, 2009, 114, 3796-3796.	1.4	4
907	Phase II Study of 5-Azacitidine and Vorinostat In Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance or Presence of Other comorbidities. Blood, 2010, 116, 604-604.	1.4	4
908	Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,. Blood, 2011, 118, 3630-3630.	1.4	4
909	Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Blood, 2011, 118, 459-459.	1.4	4
910	Outcome Of Patients (pts) With Myelofibrosis (MF) After Ruxolutinib (Rux) Therapy. Blood, 2013, 122, 1584-1584.	1.4	4
911	Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years. Blood, 2014, 124, 1350-1350.	1.4	4
912	A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Blood, 2014, 124, 3252-3252.	1.4	4
913	A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are NaÃ¯ve, Refractory to or Have Relapsed on 5-Azacitadine: a Preliminary Analysis. Blood, 2014, 124, 3263-3263.	1.4	4
914	Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). Blood, 2014, 124, 4565-4565.	1.4	4
915	First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2014, 124, 529-529.	1.4	4
916	An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies. Blood, 2014, 124, 530-530.	1.4	4
917	Survivorship in APL- Outcomes of Acute Promyelocytic Leukemia (APL) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years. Blood, 2014, 124, 954-954.	1.4	4
918	Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI). Blood, 2015, 126, 1587-1587.	1.4	4

#	Article	IF	Citations
919	Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs). Blood, 2015, 126, 1696-1696.	1.4	4
920	Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia. Blood, 2015, 126, 4779-4779.	1.4	4
921	5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). Blood, 2015, 126, 823-823.	1.4	4
922	Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood, 2016, 128, 1641-1641.	1.4	4
923	Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study. Blood, 2016, 128, 3167-3167.	1.4	4
924	Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECTÂ® Myelodysplastic Syndromes (MDS) and AML Disease Registry. Blood, 2016, 128, 3548-3548.	1.4	4
925	Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood, 2016, 128, 940-940.	1.4	4
926	p38 MAPK in MDS. Aging, 2015, 7, 346-347.	3.1	4
927	Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.. Blood, 2009, 114, 509-509.	1.4	4
928	A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse.. Blood, 2009, 114, 1061-1061.	1.4	4
929	Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 and Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction. Blood, 2010, 116, 2706-2706.	1.4	4
930	EphrinB1 Activation As a Potential New Treatment Option in AML. Blood, 2011, 118, 5235-5235.	1.4	4
931	Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.. Blood, 2012, 120, 2562-2562.	1.4	4
932	MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS. Blood, 2013, 122, 3340-3340.	1.4	4
933	North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. Blood, 2015, 126, 1138-1138.	1.4	4
934	Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Blood, 2021, 138, 701-701.	1.4	4
935	Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study. Blood, 2021, 138, 1524-1524.	1.4	4
936	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. American Journal of Hematology, 2022, 97, 885-894.	4.1	4

#	Article	IF	Citations
937	Progress in Myelodysplastic Syndromes. Clinical Lymphoma and Myeloma, 2009, 9, S286-S292.	1.4	3
938	Standard Therapy for Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 303-313.	0.4	3
939	Evaluation of epidemiological factors in survival of patients with de novo myelodysplastic syndromes. Cancer Causes and Control, 2014, 25, 425-435.	1.8	3
940	Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 1012-1015.	1.3	3
941	Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a PhaseÂIIIÂTrial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 213-219.e4.	0.4	3
942	Fidelity of peripheral blood for monitoring genomics and tumor immuneâ€microenvironment in myelodysplastic syndromes. EJHaem, 2020, 1, 552-557.	1.0	3
943	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leukemia and Lymphoma, 2022, 63, 199-204.	1.3	3
944	What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?. Blood, 2018, 132, 3098-3098.	1.4	3
945	Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial. Blood, 2019, 134, 2999-2999.	1.4	3
946	Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO. Blood, 2019, 134, 3851-3851.	1.4	3
947	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. Blood, 2019, 134, 4581-4581.	1.4	3
948	A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC). Blood, 2019, 134, 2652-2652.	1.4	3
949	Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration. Blood, 2019, 134, 2957-2957.	1.4	3
950	Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS). Blood, 2019, 134, 4268-4268.	1.4	3
951	A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy. Blood, 2019, 134, 2927-2927.	1.4	3
952	Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML).. Blood, 2005, 106, 1099-1099.	1.4	3
953	Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP).. Blood, 2005, 106, 1103-1103.	1.4	3
954	Chemo-Immunotherapy with Hyper-CVAD Plus Ritixumab for Adult Burkittâ€™s and Burkittâ€™s Type Lymphoma (BL) or Acute Lymphoblastic Leukemia (B-ALL).. Blood, 2005, 106, 149-149.	1.4	3

#	Article	IF	Citations
955	Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. Blood, 2005, 106, 1830-1830.	1.4	3
956	Cytopenias in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib (SPRYCELÂ®): Clinical Features and Management, Including Outcome after Hematopoietic Growth Factor Therapy.. Blood, 2006, 108, 2163-2163.	1.4	3
957	Phase I Study of 5-aza-2â€²-Deoxycitidine, Alone or in Combination with Hyper-CVAD, in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).. Blood, 2007, 110, 2826-2826.	1.4	3
958	Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy. Blood, 2008, 112, 2987-2987.	1.4	3
959	Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years. Blood, 2008, 112, 768-768.	1.4	3
960	A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents.. Blood, 2009, 114, 1758-1758.	1.4	3
961	Augmented Hyper-CVAD in Adult ALL Salvage Therapy: The MDACC Experience of Hyper-CVAD Using Dose-Intense Vincristine, Dexamethasone, and Pegaspargase.. Blood, 2009, 114, 2031-2031.	1.4	3
962	Count Recovery in AML Patients Achieving a Complete Response.. Blood, 2009, 114, 2062-2062.	1.4	3
963	Comorbidities and Myelodysplatic Syndromes.. Blood, 2009, 114, 2789-2789.	1.4	3
964	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Deferasirox (ExjadeÂ®) in Patients with Low/Intermediate-1 Risk MDS and Transfusional Iron Overload.. Blood, 2009, 114, 4854-4854.	1.4	3
965	A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents. Blood, 2010, 116, 1857-1857.	1.4	3
966	Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS. Blood, 2010, 116, 3298-3298.	1.4	3
967	The Achievement of An Early Complete Cytogenetic Response (CCyR) Is A Major Determinant for Outcome In Patients (pts) with Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs).. Blood, 2010, 116, 3429-3429.	1.4	3
968	Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML). Blood, 2011, 118, 1546-1546.	1.4	3
969	Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes. Blood, 2011, 118, 1720-1720.	1.4	3
970	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. Blood, 2012, 120, 311-311.	1.4	3
971	The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP). Blood, 2012, 120, 72-72.	1.4	3
972	Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy. Blood, 2013, 122, 2654-2654.	1.4	3

#	Article	IF	Citations
973	A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents. Blood, 2013, 122, 2752-2752.	1.4	3
974	Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML). Blood, 2013, 122, 5011-5011.	1.4	3
975	Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA). Blood, 2014, 124, 3273-3273.	1.4	3
976	Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). Blood, 2014, 124, 3671-3671.	1.4	3
977	Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2016, 128, 1606-1606.	1.4	3
978	Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3-ITDmutation. Blood, 2016, 128, 1611-1611.	1.4	3
979	Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures. Blood, 2016, 128, 1640-1640.	1.4	3
980	Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2011-2011.	1.4	3
981	A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2016, 128, 226-226.	1.4	3
982	Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2016, 128, 4322-4322.	1.4	3
983	Effect of Failure To Respond to Targeted Therapy on Response to Cytotoxic Therapy in Pts Age â‰¥ 60 with Newly-Diagnosed AML.. Blood, 2006, 108, 1965-1965.	1.4	3
984	Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 2189-2189.	1.4	3
985	A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS). Blood, 2013, 122, 2751-2751.	1.4	3
986	Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 940-940.	1.4	3
987	Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2019, 134, 2577-2577.	1.4	3
988	Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data. Blood, 2019, 134, 291-291.	1.4	3
989	Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2021, 138, 3421-3421.	1.4	3
990	Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood, 2021, 138, 1233-1233.	1.4	3

#	Article	IF	Citations
991	Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML). Blood, 2021, 138, 2330-2330.	1.4	3
992	Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2021, 138, 367-367.	1.4	3
993	Leukemia and lymphoma: what is the role for intrathecal prophylactic treatment in adults?. Expert Review of Neurotherapeutics, 2004, 4, S25-S31.	2.8	2
994	Decitabine in Myelodysplastic Syndromes. Drugs, 2006, 66, 959-960.	10.9	2
995	Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. Leukemia and Lymphoma, 2014, 55, 1425-1427.	1.3	2
996	Ruxolitinib (RUX) in combination with 5-Azacytidine (AZA) as therapy for patients with myelofibrosis (MF). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S59.	0.4	2
997	Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S256-S257.	0.4	2
998	Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. American Journal of Hematology, 2018, 93, E357-E360.	4.1	2
999	Blast-phase chronic myelomonocytic leukemia: more than just semantics. Leukemia, 2018, 32, 2093-2094.	7.2	2
1000	Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leukemia and Lymphoma, 2019, 60, 3172-3180.	1.3	2
1001	Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. British Journal of Haematology, 2020, 191, e10-e13.	2.5	2
1002	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). American Journal of Hematology, 2020, 95, E326-E329.	4.1	2
1003	Results of a Phase 1/2a doseâ€“escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leukemia and Lymphoma, 2020, 61, 1943-1953.	1.3	2
1004	Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2018, 132, 1548-1548.	1.4	2
1005	Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. Blood, 2018, 132, 4367-4367.	1.4	2
1006	Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience. Blood, 2018, 132, 5447-5447.	1.4	2
1007	Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203. Blood, 2018, 132, 1403-1403.	1.4	2
1008	Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. Blood, 2018, 132, 3983-3983.	1.4	2

#	Article	IF	Citations
1009	Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease. Blood, 2018, 132, 5212-5212.	1.4	2
1010	Safety and Efficacy of Non-Irradiated Granulocyte Transfusions (GTX) in Neutropenic Patients with Severe or Refractory Abdominal Infections: A Single Center Retrospective Analysis of 119 Transfusions in 22 Patients. Blood, 2018, 132, 3815-3815.	1.4	2
1011	KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice. Blood, 2019, 134, 562-562.	1.4	2
1012	Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy. Blood, 2019, 134, 735-735.	1.4	2
1013	Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. Blood, 2019, 134, 47-47.	1.4	2
1014	Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood, 2019, 134, 2642-2642.	1.4	2
1015	Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes. Blood, 2019, 134, 1715-1715.	1.4	2
1016	Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response. Blood, 2019, 134, 3846-3846.	1.4	2
1017	Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. Blood, 2019, 134, 2582-2582.	1.4	2
1018	A Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies.. Blood, 2004, 104, 1802-1802.	1.4	2
1019	Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.. Blood, 2004, 104, 272-272.	1.4	2
1020	A Phase II Study of Temsirolimus (CCI-779) in Patients with Advanced Leukemias.. Blood, 2004, 104, 4523-4523.	1.4	2
1021	Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) â‰¥ 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML).. Blood, 2005, 106, 2804-2804.	1.4	2
1022	Detection of Residual p73 DNA Methylation Predicts for Shorter Disease Free and Overall Survival in Patients (pts) with Philadelphia (Ph) Chromosome Negative Acute Lymphocytic Leukemia (ALL) in Remission.. Blood, 2006, 108, 2333-2333.	1.4	2
1023	Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen.. Blood, 2007, 110, 115-115.	1.4	2
1024	Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome.. Blood, 2007, 110, 1455-1455.	1.4	2
1025	Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia Associated with Chromosome 5 Abnormalities.. Blood, 2007, 110, 1459-1459.	1.4	2
1026	A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia.. Blood, 2007, 110, 1842-1842.	1.4	2

#	Article	IF	Citations
1027	Pegylated Interferon-alfa-2a (PEG-IFN-Î±-2A; PEGASYSâ„¢) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.. Blood, 2007, 110, 3542-3542.	1.4	2
1028	Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 (ALL).. Blood, 2007, 110, 4324-4324.	1.4	2
1029	Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study.. Blood, 2008, 112, 1134-1134.	1.4	2
1030	Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib.. Blood, 2008, 112, 2112-2112.	1.4	2
1031	Identification of Multiple Promoter Associated CpG Islands Commonly Methylated in Both Acute Lymphocytic Leukemia (ALL) and Chronic Lymphocytic Leukemia(CLL) Using Novel Genome-Wide Microarray Technique: Implications for Common Primordial Molecular Pathways in Lymphoid Leukemias.. Blood, 2008, 112, 2263-2263.	1.4	2
1032	Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome.. Blood, 2009, 114, 118-118.	1.4	2
1033	Baseline Serum Ferritin Predicts Rate of Infection in Patients with Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.. Blood, 2009, 114, 1611-1611.	1.4	2
1034	Myelodysplastic Syndrome with Fibrosis: Experience of a Single-Institution with 139 Patients.. Blood, 2009, 114, 2775-2775.	1.4	2
1035	Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.. Blood, 2009, 114, 3819-3819.	1.4	2
1036	Lack of IKZF1 Aberrant DNA Methylation in Acute Lymphocytic Leukemia.. Blood, 2009, 114, 982-982.	1.4	2
1037	Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML).. Blood, 2010, 116, 1232-1232.	1.4	2
1038	Discrepancy In Diagnosis of Myelodysplastic Syndrome (MDS) Between Referral and Tertiary Care Centers: Experience at MD Anderson Cancer Center (MDACC). Blood, 2010, 116, 1870-1870.	1.4	2
1039	Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia. Blood, 2011, 118, 2698-2698.	1.4	2
1040	FLT3 Inhibitors Are Promising Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Patients with FLT3-ITD Mutations,. Blood, 2011, 118, 3623-3623.	1.4	2
1041	Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen. Blood, 2012, 120, 3572-3572.	1.4	2
1042	A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2012, 120, 3587-3587.	1.4	2
1043	Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update. Blood, 2012, 120, 3588-3588.	1.4	2
1044	Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms. Blood, 2012, 120, 3606-3606.	1.4	2

#	Article	IF	Citations
1045	Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis At 36 Months. Blood, 2012, 120, 3800-3800.	1.4	2
1046	Expression Of Immune Checkpoints PD-L1, PD-L2, PD-1 and CTLA4 Predict For Prognosis and Resistance To Hypomethylating Agents (HMAs) In Myelodysplastic Syndromes (MDS). Blood, 2013, 122, 2767-2767.	1.4	2
1047	Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia. Blood, 2013, 122, 3971-3971.	1.4	2
1048	Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression. Blood, 2014, 124, 2642-2642.	1.4	2
1049	Comparison of Symptom Burden in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2014, 124, 2652-2652.	1.4	2
1050	A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities. Blood, 2014, 124, 3277-3277.	1.4	2
1051	Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). Blood, 2014, 124, 4640-4640.	1.4	2
1052	Clinical Outcome of De Novo Adult Acute Lymphoblastic Leukemia (ALL) with 11q23/Mixed Lineage Leukemia (MLL) Gene Rearrangements. Blood, 2014, 124, 5342-5342.	1.4	2
1053	Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML). Blood, 2014, 124, 947-947.	1.4	2
1054	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 964-964.	1.4	2
1055	Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin. Blood, 2015, 126, 1298-1298.	1.4	2
1056	Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia. Blood, 2015, 126, 1577-1577.	1.4	2
1057	TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53. Blood, 2015, 126, 1681-1681.	1.4	2
1058	Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial. Blood, 2015, 126, 1691-1691.	1.4	2
1059	Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC). Blood, 2015, 126, 1697-1697.	1.4	2
1060	Clinical Impact of First Complete Remission (CR1) Duration on Outcome of Patients with Relapsed Philadelphia Negative Pre-B Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 2504-2504.	1.4	2
1061	Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab. Blood, 2015, 126, 2530-2530.	1.4	2
1062	Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures. Blood, 2015, 126, 3800-3800.	1.4	2

#	Article	IF	Citations
1063	Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. Blood, 2015, 126, 564-564.	1.4	2
1064	High-Risk Subtype of Ph-like Acute Lymphoblastic Leukemia (ALL) in Adults: Dismal Outcomes of CRLF2+ ALL Patients Treated with Intensive Chemotherapy. Blood, 2016, 128, 1082-1082.	1.4	2
1065	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 112-112.	1.4	2
1066	Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. Blood, 2016, 128, 1612-1612.	1.4	2
1067	Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Blood, 2016, 128, 177-177.	1.4	2
1068	Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). Blood, 2016, 128, 1919-1919.	1.4	2
1069	CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US. Blood, 2016, 128, 1923-1923.	1.4	2
1070	A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) with Poor Performance Status, Comorbidities, Other Active Malignancies or Organ Dysfunction Not Eligible for Conventional Clinical Trials. Blood, 2016, 128, 1999-1999.	1.4	2
1071	Elevated Ferritin Predicts for Inferior Survival in Patients with Acute Leukemia and May be an Early Marker of a Underlying Systemic Pathologic Inflammation. Blood, 2016, 128, 2791-2791.	1.4	2
1072	Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2817-2817.	1.4	2
1073	Pure Erythroid Leukemia Is Characterized By TP53mutations, a Complex Karyotype with Chromosome 17 Abnormalities, and Adverse Risk Independent of Therapy Type. Blood, 2016, 128, 2852-2852.	1.4	2
1074	Overexpression of KDM6B, an Epigenetic and Innate Immune Regulator, Results in Hematopoietic Alterations of Mice Including Changes in Hematopoietic Stem Cells. Blood, 2016, 128, 3149-3149.	1.4	2
1075	Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. Blood, 2016, 128, 3171-3171.	1.4	2
1076	STAG2 Mutations Are an Independent Prognostic Factor in Patients with Myelodysplastic Syndromes. Blood, 2016, 128, 3182-3182.	1.4	2
1077	Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. Blood, 2016, 128, 3975-3975.	1.4	2
1078	Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Blood, 2016, 128, 757-757.	1.4	2
1079	The Role of Chip-Related DNA Damage Response Dysfunction in Therapy-Related Myeloid Neoplasms. Blood, 2016, 128, 958-958.	1.4	2
1080	Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.. Journal of Clinical Oncology, 2017, 35, 7034-7034.	1.6	2

#	Article	IF	Citations
1081	All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).. Blood, 2007, 110, 1834-1834.	1.4	2
1082	A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Blood, 2011, 118, 967-967.	1.4	2
1083	Serum Amyloid Protein A 1 (hSAA1) Is Overexpressed in Myelodysplastic Syndromes and Potentially Mediates Toll-Like Receptor 2 Innate Immunity Signaling in CD34+ Hematopoietic Stem Cells. Blood, 2012, 120, 1703-1703.	1.4	2
1084	A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations. Blood, 2013, 122, 2684-2684.	1.4	2
1085	Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy. Blood, 2013, 122, 2788-2788.	1.4	2
1086	Increased Number of Driver Mutations Is a Predictor of Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes. Blood, 2016, 128, 51-51.	1.4	2
1087	Clinical Heterogeneity of AML Is Associated with Mutational Heterogeneity. Blood, 2018, 132, 5240-5240.	1.4	2
1088	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2018, 132, 2722-2722.	1.4	2
1089	Addition of Gemtuzumab Ozogamicin (GO) to Fludarabine, Cytarabine and G-CSF (FLAG) Based Induction Regimen Results in Better Early Molecular Response and Relapse Free Survival Compared to Idarubicin (FLAG-Ida) in Newly Diagnosed Core Binding Factor Leukemia. Blood, 2018, 132, 3993-3993.	1.4	2
1090	Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia. Blood, 2018, 132, 3013-3013.	1.4	2
1091	Single-Cell RNA Sequencing Reveals Distinct Hematopoietic Stem Cell Hierarchies in MDS. Blood, 2019, 134, 771-771.	1.4	2
1092	Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML. Blood, 2021, 138, 794-794.	1.4	2
1093	Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial. Blood, 2021, 138, 538-538.	1.4	2
1094	Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood, 2021, 138, 2323-2323.	1.4	2
1095	The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors. Blood, 2021, 138, 2554-2554.	1.4	2
1096	Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect Â® Myeloid Disease Registry. Blood, 2021, 138, 3686-3686.	1.4	2
1097	Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax. Blood, 2021, 138, 1304-1304.	1.4	2
1098	A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS). Blood, 2021, 138, 3704-3704.	1.4	2

#	Article	IF	Citations
1099	Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents. Blood, 2021, 138, 3674-3674.	1.4	2
1100	A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-NaÃ¯ve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2021, 138, 245-245.	1.4	2
1101	Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations. Blood, 2021, 138, 1536-1536.	1.4	2
1102	Evaluating new treatment options for MDS. Clinical Advances in Hematology and Oncology, 2007, 5, 1-9; quiz 10-2.	0.3	2
1103	Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia, 2022, 36, 2097-2107.	7.2	2
1104	Introduction: Advances in Myelodysplastic Syndromes. Seminars in Oncology, 2011, 38, 612.	2.2	1
1105	Nontransplantation Options for Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2011, 17, S9-S10.	2.0	1
1106	Myelodysplastic syndromes should been renamed as myelodysplastic neoplasms. Leukemia Research, 2013, 37, 463-464.	0.8	1
1107	Acute Myeloid Leukemia (AML) Following Myelodysplastic Syndrome (MDS) and Failure ofÂTherapy with Hypomethylating Agents (HMA): An Emerging Entity With a Poor Prognosis. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S379.	0.4	1
1108	A Phase II Expansion Study of Vorinostat in Combination With Idarubicin and Cytarabine for Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S123.	0.4	1
1109	Optimized Voronoi compartment determination using machine-learning to identify prognostic groups of patients based on cellular behavior in treated AML. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S22.	0.4	1
1110	Inotuzumab ozogamicin in combination with mini-hyper-CVD as salvage therapy for patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S6.	0.4	1
1111	Randomized Phase II Study of Clofarabine or Fludarabine Combined with Idarubicin and Cytarabine for the Treatment of Newly Diagnosed AML. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S18.	0.4	1
1112	Outcomes after Blinatumomab Failure in Patients with Relapsed/ Refractory (R/R) B-cell ALL (ALL). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S12-S13.	0.4	1
1113	Th1/17 Hybrid CD4 + Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S10.	0.4	1
1114	Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S257-S258.	0.4	1
1115	Improving Prognostic Tools for Patients With Myelodysplastic Syndromes. Mayo Clinic Proceedings, 2018, 93, 1340-1342.	3.0	1
1116	Investigating protein patterns in human leukemia cell line experiments: A Bayesian approach for extremely small sample sizes. Statistical Methods in Medical Research, 2020, 29, 1181-1196.	1.5	1

#	Article	IF	Citations
1117	MDS-141: The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S315-S316.	0.4	1
1118	MDS/MPN-RS-T justified inclusion as a unique disease entity?. Best Practice and Research in Clinical Haematology, 2020, 33, 101147.	1.7	1
1119	Associations between complete remission and 2- to 3-year survival following 7â€‰+â€‰3 induction for acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 1967-1972.	1.3	1
1120	MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very Highâ€“Risk Myelodysplastic Syndromes (MDS). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S348-S349.	0.4	1
1121	Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the ConnectÂ® MDS/AML Disease Registry. Blood, 2018, 132, 4731-4731.	1.4	1
1122	Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood, 2018, 132, 2674-2674.	1.4	1
1123	Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Blood, 2018, 132, 2667-2667.	1.4	1
1124	Characteristics and Outcomes of Patients (pts) with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adults: A Single-Center, Prospective Analysis of 36 Pts. Blood, 2018, 132, 3689-3689.	1.4	1
1125	Phase 2 Study of Lenalidomide Maintenance for Patients with High-Risk Acute Myeloid Leukemia in Remission. Blood, 2018, 132, 2714-2714.	1.4	1
1126	Predictors of Outcomes in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at First Relapse in the Era of Tyrosine Kinase Inhibitors. Blood, 2018, 132, 2659-2659.	1.4	1
1127	Weight Increase during Induction Therapy Predicts Intensive Care Unit (ICU) Transfer in Patients (Pts) with Acute Promyelocytic Leukemia (APL). Blood, 2018, 132, 4003-4003.	1.4	1
1128	Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (â‰65 yrs) with Acute Myeloid Leukemia. Blood, 2018, 132, 4039-4039.	1.4	1
1129	Induced PD-1 Expression on Bone Marrow CD34+ Cells from MDS Patients Treated with 5-Azacitadine in Combination with Nivolumab and/or Ipilimumab. Blood, 2018, 132, 1807-1807.	1.4	1
1130	Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up. Blood, 2018, 132, 3011-3011.	1.4	1
1131	Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Peripheral Blood and Bone Marrow Genomic Analysis. Blood, 2019, 134, 2592-2592.	1.4	1
1132	Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm). Blood, 2019, 134, 1447-1447.	1.4	1
1133	Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30). Blood, 2019, 134, 3015-3015.	1.4	1
1134	Chromosomal Abnormalities in Philadelphia Chromosome (Ph)-Negative Metaphases Appearing during Imatinib Mesylate (IM) Therapy in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase.. Blood, 2005, 106, 1090-1090.	1.4	1

#	Article	IF	Citations
1135	Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.. Blood, 2005, 106, 1840-1840.	1.4	1
1136	A Pilot Trial of Imatinib, Low-Dose Cytarabine (ara-C) and Idarubicin (Ida) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Myeloid Blastic Phase (BP).. Blood, 2005, 106, 4840-4840.	1.4	1
1137	Secondary Leukemia after Imatinib Mesylate (IM) Therapy for Chronic Myelogenous Leukemia (CML).. Blood, 2005, 106, 4862-4862.	1.4	1
1138	A Phase II Study of Azacitidine (Vidazaâ„¢) for Patients with Myelofibrosis (MF).. Blood, 2006, 108, 2706-2706.	1.4	1
1139	Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections.. Blood, 2006, 108, 4483-4483.	1.4	1
1140	Prognostic Significance of Î²-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients.. Blood, 2006, 108, 802-802.	1.4	1
1141	Analysis of Class I and II Histone Deacetylase Fails To Identify a Human Leukemia Specific Expression Profile.. Blood, 2007, 110, 2130-2130.	1.4	1
1142	Randomized Study of Decitabine Versus Observation or Continued Cytotoxic Chemotherapy in Patients with Intermediate and Poor Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission.. Blood, 2007, 110, 2859-2859.	1.4	1
1143	Survival Outcomes for Patients (Pts) with Chronic Myeloid Leukemia (CML) with Clonal Evolution (CE) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure.. Blood, 2007, 110, 2949-2949.	1.4	1
1144	Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.. Blood, 2008, 112, 2126-2126.	1.4	1
1145	Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy. Blood, 2008, 112, 2955-2955.	1.4	1
1146	Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations. Blood, 2008, 112, 3302-3302.	1.4	1
1147	Epigenetic Silencing of the RUNX3 Gene by Promoter Hypermethylation in Patients with Acute Myeloid Leukemia.. Blood, 2008, 112, 3341-3341.	1.4	1
1148	Combined Therapy with Lenalidomide and Prednisone Renders Durable Clinical, Histopathological, and Molecular Responses in Patients with Myelofibrosis. Blood, 2008, 112, 662-662.	1.4	1
1149	Intracranial Hemorrhage (ICH) In Patients (Pts) Presenting with Myeloid Leukemia to a Tertiary Care Center. Blood, 2010, 116, 2170-2170.	1.4	1
1150	The Achievement of a 3-Month Complete Cytogenetic Response (3-mo CCyR) to Second Generation (2nd) Tyrosine Kinase Inhibitors (TKI) Post Imatinib Failure Is the Only Predictive Factor for Event-Free (EFS) and Overall Survival (OS). Blood, 2010, 116, 2289-2289.	1.4	1
1151	Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants.. Blood, 2010, 116, 2831-2831.	1.4	1
1152	Impact of RAS Mutations In Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 2926-2926.	1.4	1

#	Article	IF	Citations
1153	Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). Blood, 2010, 116, 4957-4957.	1.4	1
1154	Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index. Blood, 2010, 116, 605-605.	1.4	1
1155	High Expression of Autophagy Related Proteins Negatively Impacts Clinical Outcomes in Acute Myelogenous Leukemiaâ€“Time to Target Autophagy to Improve Therapy Outcomes?. Blood, 2011, 118, 2513-2513.	1.4	1
1156	Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. Blood, 2012, 120, 1519-1519.	1.4	1
1157	Phase 1 Study of ABT-348, A Dual Aurora/VEGF-Receptor Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies.. Blood, 2012, 120, 2617-2617.	1.4	1
1158	Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.. Blood, 2012, 120, 2627-2627.	1.4	1
1159	Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood, 2012, 120, 3619-3619.	1.4	1
1160	Induction of PD-1 and PD-1 Ligand Expression by Hypomethylating Agents (HMA) in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Suggest a Role for T Cell Function in Clinical Resistance to Hmas. Blood, 2012, 120, 3810-3810.	1.4	1
1161	Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2012, 120, 742-742.	1.4	1
1162	Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center. Blood, 2012, 120, 918-918.	1.4	1
1163	Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy. Blood, 2013, 122, 1525-1525.	1.4	1
1164	DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML. Blood, 2013, 122, 1548-1548.	1.4	1
1165	Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. Blood, 2013, 122, 305-305.	1.4	1
1166	Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience. Blood, 2013, 122, 3917-3917.	1.4	1
1167	Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2013, 122, 3949-3949.	1.4	1
1168	Prognostic Factors For Outcome In Patients (pts) With Myelofibrosis (MF) Treated With Ruxolitinib (Rux). Blood, 2013, 122, 4050-4050.	1.4	1
1169	Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia. Blood, 2014, 124, 1015-1015.	1.4	1
1170	Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. Blood, 2014, 124, 4666-4666.	1.4	1

#	Article	IF	Citations
1171	Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. Blood, 2014, 124, 534-534.	1.4	1
1172	Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure. Blood, 2015, 126, 1335-1335.	1.4	1
1173	Long Non-Coding RNA Induces De Novo Myelodysplastic Syndrome through Epigenetic Regulation. Blood, 2015, 126, 1640-1640.	1.4	1
1174	Fusion Transcript Reduction in Core Binding Factor Acute Myeloid Leukemia: Maintenance Strategy with Hypomethylating Agents. Blood, 2015, 126, 2604-2604.	1.4	1
1175	Seven Year Follow up of Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib 400 Mg Twice Daily - a Single Center Study at MDACC. Blood, 2015, 126, 2796-2796.	1.4	1
1176	Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 2877-2877.	1.4	1
1177	Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes. Blood, 2015, 126, 2879-2879.	1.4	1
1178	Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure. Blood, 2015, 126, 3718-3718.	1.4	1
1179	Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia. Blood, 2015, 126, 3756-3756.	1.4	1
1180	Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia. Blood, 2015, 126, 3804-3804.	1.4	1
1181	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia. Blood, 2015, 126, 4347-4347.	1.4	1
1182	Long-Term Experience with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 111-111.	1.4	1
1183	Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. Blood, 2016, 128, 2916-2916.	1.4	1
1184	Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens. Blood, 2016, 128, 2917-2917.	1.4	1
1185	Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy. Blood, 2016, 128, 3166-3166.	1.4	1
1186	Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). Blood, 2016, 128, 4246-4246.	1.4	1
1187	Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes. Blood, 2016, 128, 4310-4310.	1.4	1
1188	Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy. Blood, 2016, 128, 4318-4318.	1.4	1

#	Article	IF	Citations
1189	Clinical Relevance of Driver Mutations and Number of Driver Mutations in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 54-54.	1.4	1
1190	Characteristics and Prognosis of Patients (pts) with Acute Megakaryocytic Leukemia (AMegL) Treated at M.D. Anderson Cancer Center Since 1987.. Blood, 2004, 104, 3003-3003.	1.4	1
1191	Prolonged Administration of Arsenic Trioxide (TrisenoxÂ®) for Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) at MD Anderson Cancer Center: A Phase II Study.. Blood, 2004, 104, 4731-4731.	1.4	1
1192	Aberrant DNA Methylation of the Src Tyrosine Kinase Hck Is a Frequent Event in Human Leukemia and May Predict for Poor Prognosis in Adult Acute Lymphocytic Leukemia (ALL).. Blood, 2004, 104, 1542-1542.	1.4	1
1193	Is the Proposed World Health Organization (WHO) Classification for Chronic Myeloid Leukemia (CML) of Clinical Value in the Imatinib Era?.. Blood, 2004, 104, 1014-1014.	1.4	1
1194	Blockade of Adaptive Defensive Changes in Cholesterol Uptake and Synthesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study.. Blood, 2005, 106, 405-405.	1.4	1
1195	Study of Intra-Venous Homoharringtonine (HHT) in the Treatment of Myelodysplastic Syndrome (MDS).. Blood, 2005, 106, 4903-4903.	1.4	1
1196	Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. Blood, 2005, 106, 2796-2796.	1.4	1
1197	Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).. Blood, 2006, 108, 2652-2652.	1.4	1
1198	RIZ1 Is Downregulated during CML Progression and Displays Tumor Suppressor Properties in CML Cell Lines.. Blood, 2006, 108, 2134-2134.	1.4	1
1199	Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial.. Blood, 2006, 108, 2320-2320.	1.4	1
1200	Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS).. Blood, 2007, 110, 884-884.	1.4	1
1201	Disease-Related Mortality in Patients with Lower-Risk Myelodysplastic Syndrome (MDS). Blood, 2008, 112, 5073-5073.	1.4	1
1202	The Combination of a Histone Deacetylase (HDAC) Inhibitor with the BCL-2 Inhibitor GX15-070 Has Synergistic Antileukemia Effect by Inducing Both Apoptotic and Autophagic Pathways.. Blood, 2008, 112, 1633-1633.	1.4	1
1203	Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy.. Blood, 2008, 112, 2111-2111.	1.4	1
1204	Genome-Wide Chip-Seq Analysis of Histone Methylation Reveals Modulators of NF-Î²B Signaling and the Histone Demethylase JMJD3 as Implicated in Disease Progression in Myelodysplastic Syndrome (MDS).. Blood, 2009, 114, 291-291.	1.4	1
1205	Antifungal Prophylaxis (AFP) for Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Undergoing Intensive Chemotherapy: An Experience with 730 Pts.. Blood, 2009, 114, 3102-3102.	1.4	1
1206	A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias.. Blood, 2009, 114, 2047-2047.	1.4	1

#	Article	IF	Citations
1207	Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) â‰¥ 60 Years (yrs).. Blood, 2009, 114, 2058-2058.	1.4	1
1208	A Phase 1 Study of Dose-Dense 5-Aza-2â€²-Deoxycitidine (decitabine) in Relapse Refractory Acute Lymphocytic Leukemia (ALL).. Blood, 2009, 114, 2030-2030.	1.4	1
1209	Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 836-836.	1.4	1
1210	A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 2188-2188.	1.4	1
1211	Levels of Nrf2 and Keap1 Are Associated with Poor Prognostic Features In Myelodysplastic Syndromes (MDS). Blood, 2010, 116, 1874-1874.	1.4	1
1212	Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab. Blood, 2010, 116, 1781-1781.	1.4	1
1213	Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP).. Blood, 2010, 116, 3442-3442.	1.4	1
1214	Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML). Blood, 2010, 116, 672-672.	1.4	1
1215	Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS). Blood, 2011, 118, 763-763.	1.4	1
1216	Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis. Blood, 2011, 118, 2598-2598.	1.4	1
1217	Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP),. Blood, 2011, 118, 3779-3779.	1.4	1
1218	Early Clearance of Peripheral Blood Blasts but Not White Blood Cells Is a Powerful Prognostic marker for complete Response and Overall Survival in Patients with Acute Myeloid Leukemia (AML) receiving Induction Chemotherapy. Blood, 2011, 118, 1553-1553.	1.4	1
1219	Impact of Npm1, Flt3, and Ras Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia,. Blood, 2011, 118, 3594-3594.	1.4	1
1220	Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts). Blood, 2011, 118, 2764-2764.	1.4	1
1221	Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML). Blood, 2012, 120, 3610-3610.	1.4	1
1222	Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2012, 120, 43-43.	1.4	1
1223	Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML).. Blood, 2012, 120, 2592-2592.	1.4	1
1224	Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2012, 120, 1456-1456.	1.4	1

#	Article	IF	Citations
1225	Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2013, 122, 2663-2663.	1.4	1
1226	Final Report Of Phase II Study Of Sorafenib and 5-Azacytidine In Patients With Relapsed Or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. Blood, 2013, 122, 3934-3934.	1.4	1
1227	Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade. Blood, 2014, 124, 949-949.	1.4	1
1228	Telomere Dysfunction-Induced DNA Damage Drives Hematopoietic Stem Cell Fate. Blood, 2015, 126, 1156-1156.	1.4	1
1229	Homoharringtonine (HHT) with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia (CML). Blood, 2016, 128, 5449-5449.	1.4	1
1230	Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 4332-4332.	1.4	1
1231	Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2018, 132, 3985-3985.	1.4	1
1232	Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML). Blood, 2018, 132, 88-88.	1.4	1
1233	Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs). Blood, 2019, 134, 2941-2941.	1.4	1
1234	The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults. Blood, 2019, 134, 4249-4249.	1.4	1
1235	Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS). Blood, 2019, 134, 2578-2578.	1.4	1
1236	Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML. Blood, 2021, 138, 4652-4652.	1.4	1
1237	High-Throughput Characterization of Cytogenomic Heterogeneity of MDS Using High-Resolution Optical Genome Mapping. Blood, 2021, 138, 105-105.	1.4	1
1238	A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood, 2021, 138, 4398-4398.	1.4	1
1239	Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. Blood, 2021, 138, 631-631.	1.4	1
1240	A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission. Blood, 2021, 138, 2326-2326.	1.4	1
1241	Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents. Blood, 2021, 138, 2613-2613.	1.4	1
1242	Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial. Blood, 2021, 138, 1517-1517.	1.4	1

#	Article	IF	Citations
1243	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Blood, 2021, 138, 1270-1270.	1.4	1
1244	Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study. Blood, 2021, 138, 3682-3682.	1.4	1
1245	Characteristics and Outcomes of Adolescent and Young Adult (AYA) Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML): A Single-Center Retrospective Analysis. Blood, 2021, 138, 3687-3687.	1.4	1
1246	A Phase I/II Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2021, 138, 3419-3419.	1.4	1
1247	Primary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with i(12p) and TP53 mutation: A report of two cases. Annals of Diagnostic Pathology, 2022, 59, 151951.	1.3	1
1248	Role of epigenetic therapy in myelodysplastic syndrome. Expert Review of Hematology, 2008, 1, 161-174.	2.2	0
1249	In reply to â€˜Improving the prognostic evaluation of patients with lower-risk myelodysplastic syndromesâ€™ by Kuendgen et al.. Leukemia, 2009, 23, 185-185.	7.2	0
1250	Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution. Leukemia and Lymphoma, 2012, 53, 1013-1014.	1.3	0
1251	Epigenetics of leukemia. , 0, , 239-256.		0
1252	Comparison of Outcome in Erythroleukemia Patients Treated with Standard Chemotherapy Regimens or Hypomethylating Agents. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S380-S381.	0.4	0
1253	Characteristics of therapy-related myeloid neoplasms in breast cancer patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S186-S187.	0.4	0
1254	Acute Myeloid Leukemia with t(v;5q33-34) Does Not Always have Myelodysplastic Features but is Associated with Poor Outcome. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S187-S188.	0.4	0
1255	Expression Of Phosphodiesterase 4 (PDE4) In Myelodysplastic Syndromes (MDS) And Its Impact On Outcome: Result Of A Transcriptome Profiling Using RNA Sequencing From 43 Patients With MDS And Chronic Myelomonocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S45-S46.	0.4	0
1256	MDS patients with TP53 mutation respond equally to hypomethylating agents (HMA) but has significantly shorter response duration compared to patients with wild type TP53. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S49.	0.4	0
1257	Secondary Hemophagocytic Lymphohistiocytoisis (HLH) in Adults Patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S76.	0.4	0
1258	Impact of Therapy-Related De Novo Acute Myeloid Leukemia on Response and Survival. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S181-S182.	0.4	0
1259	Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S5.	0.4	0
1260	A Phase II Trial of Low-Dose Hypomethylating Agents in Patients with Low- or Intermediate-1-Risk MDS. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S88-S89.	0.4	0

#	Article	IF	Citations
1261	Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL): A Phase II Study. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S10-S11.	0.4	0
1262	Update Results of Frontline Therapy with Combination of Hyper-CMAD with Liposomal Vincristine (M) in Patients (Pts) with ALL (ALL). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S11-S12.	0.4	0
1263	A Phase II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy for Patients with Relapsed/Refractory ALL. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S15-S16.	0.4	0
1264	A Phase II Trial of Inotuzumab Ozogamicin Combined with Mini-HyperCVD as Salvage Therapy for Relapsed/Refractory ALL. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S264-S265.	0.4	0
1265	Novel EZH2 Mutation in a Patient with Second Primary B-Cell Acute Lymphoblastic Leukemia after del5q Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S349.	0.4	0
1266	Immune Checkpoint Based Approaches in AML. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S45-S46.	0.4	0
1267	Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S255-S256.	0.4	0
1268	The Landscape of Genotype-Phenotype Correlation in AML. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S209-S210.	0.4	0
1269	MEK Inhibitor Binimetinib (MEK162) in Relapse and Refractory Acute Myeloid Leukemia: Results of a Phase I/II Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S199.	0.4	0
1270	Myelodysplastic Syndromes with EZH2 Mutations Frequently Show Multilineage Dysplasia, Chromosome 7 Alterations and Concomitant Mutations in ASXL1, RUNX1 and TET2. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S260.	0.4	0
1271	Secondary primary cancers before and after myeloid neoplasia: a two-way street. Lancet Haematology,the, 2018, 5, e328-e329.	4.6	0
1272	Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S181.	0.4	0
1273	Evolution of the AML Genome and Epigenome during IDH Inhibitor Therapy and their Association with Clinical Response and Resistance. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S238-S239.	0.4	0
1274	Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S180-S181.	0.4	0
1275	Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S186.	0.4	0
1276	ALL-216: Outcomes of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Molecular Response at Three Months of Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S164-S165.	0.4	0
1277	AML-314: Post-Transplant Cyclophosphamide Reduces the Incidence of Acute Graft Versus Host Disease in AML/MDS Patients Who Receive Checkpoint Inhibitors After Allogeneic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S201-S202.	0.4	0
1278	AML-318: Predictors of Outcomes in AML with MLL Rearrangement. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S202-S203.	0.4	0

#	Article	IF	Citations
1279	MDS-179: Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S318-S319.	0.4	0
1280	Daratumumab in transfusionâ€dependent patients with low or intermediateâ€<scp>1</scp> risk myelodysplastic syndromes. American Journal of Hematology, 2021, 96, E111-E114.	4.1	0
1281	Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203. Leukemia and Lymphoma, 2021, 62, 1774-1777.	1.3	0
1282	Use of Oral Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S73-S76.	0.4	0
1283	MDS-439: A Simplified Three-Marker Panel for Myelodysplastic Syndrome Prognostic Outperforms the Well-Established Revised International Prognostic Scoring Systems (IPSS-R). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S351.	0.4	0
1284	MDS-404: Population Pharmacokinetics Modeling and Evaluation of Clinical Efficacy and Safety of Sabatolimab: Dose Selection and Dose-Response Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S349-S350.	0.4	0
1285	Poster: MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-NaÃ¯ve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S227.	0.4	0
1286	Poster: MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very Highâ€"Risk Myelodysplastic Syndromes (MDS). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S230.	0.4	0
1287	Poster: AML-204: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S213.	0.4	0
1288	AML-291: Treatment Response and Outcome in DNMT3A-mutated Acute Myeloblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S301-S302.	0.4	0
1289	2 Chlorodeoxyadenosine (2-CdA) and Cytarabine (ara-C) Combination Is Effective and Safe in Idiopathic Hypereosinophilic Syndrome (HES).. Blood, 2004, 104, 4764-4764.	1.4	0
1290	Detection of Aberrant DNA Methylation in Acute Lymphocytic Leukemia (ALL) Using a Real-Time Polymerase Chain Reaction (PCR) Assay.. Blood, 2004, 104, 998-998.	1.4	0
1291	Survival Advantage for Patients (pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Treated with Imatinib.. Blood, 2004, 104, 1006-1006.	1.4	0
1292	Intracranial Hemorrhage (ICH) in Patients (pts) with Newly Diagnosed Leukemia: Incidence and Effect on Outcome.. Blood, 2004, 104, 4530-4530.	1.4	0
1293	Phase I Study of Clofarabine Plus Idarubicin and Clofarabine Plus Idarubicin Plus Cytarabine (ARA-C) in Patients (PTS) with Relapsed and Primary Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloid Blast Phase of Chronic Myeloid Leukemia (CML).. Blood, 2004, 104, 1809-1809.	1.4	0
1294	Phase I Study of TriapineÂ® and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndrome (MDS).. Blood, 2005, 106, 4925-4925.	1.4	0
1295	Clofarabine Combinations in Acute Myeloid Leukemia (AML) Salvage: A Dose-Finding Phase I Study of Clofarabine Plus Idarubicin and Clofarabine/Idarubicin Plus Cytarabine (ara-C).. Blood, 2005, 106, 2803-2803.	1.4	0
1296	Aberrant DNA Methylation of a Cell Cycle Regulatory Pathway Composed of p73, p15 and P57kip2 Is Associated with Poor Prognosis in Adult Patients with Philadelphia Chromosome Negative Acute Lymphocytic Leukemia (ALL).. Blood, 2005, 106, 481-481.	1.4	0

#	Article	IF	Citations
1297	Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.. Blood, 2006, 108, 2705-2705.	1.4	0
1298	Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).. Blood, 2006, 108, 1861-1861.	1.4	0
1299	Clinical Significance of Loss of Chromosome Y (â^'Y) in Patients with Chronic Myeloid Leukemia (CML): Is It Clonal Evolution?.. Blood, 2006, 108, 2117-2117.	1.4	0
1300	Phase I Trial of Sphingosomal Vincristine (SV, MarqiboÂ®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).. Blood, 2006, 108, 4539-4539.	1.4	0
1301	Incidence of Venothromboembolism (VTE) in Patients (pts) with Acute Lymphocytic Leukemia (ALL), Burkittâ€™s Leukemia/Lymphoma (BL) or Lymphoblastic Leukemia (LL).. Blood, 2006, 108, 4534-4534.	1.4	0
1302	Methylation Profiling of Three Homogenous Cancers: Chronic Myelogenous Leukemia (CML), Acute Promyelocytic Leukemia (APL) and Gastrointestinal Stromal Tumors (GIST).. Blood, 2006, 108, 736-736.	1.4	0
1303	PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.. Blood, 2006, 108, 3636-3636.	1.4	0
1304	Frequency of NUP214-ABL1 Oncogene in Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Analysis of the Activity of Imatinib and Nilotinib in NUP214-ABL1-Expressing T-ALL Cell Lines.. Blood, 2006, 108, 710-710.	1.4	0
1305	Phase I Study of XL-119, a Rebeccamycin Analog, in Patients with Refractory Hematological Malignancies.. Blood, 2006, 108, 1969-1969.	1.4	0
1306	Changes in DNA Methylation of Repetitive Elements during the Progression of Chronic Myelogenous Leukemia.. Blood, 2006, 108, 4302-4302.	1.4	0
1307	Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.. Blood, 2006, 108, 2612-2612.	1.4	0
1308	Treatment of Myelodysplastic Syndrome (MDS) with Cytokine Immunotherapy for Low-Risk MDS.. Blood, 2007, 110, 1463-1463.	1.4	0
1309	Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.. Blood, 2007, 110, 3545-3545.	1.4	0
1310	Genome-Wide DNA Methylation Profile of CLL with 17p del Allowed Identification of Multiple Epigenetically Inactivated Molecular Pathways with Prognostic Value in Human Leukemia.. Blood, 2007, 110, 492-492.	1.4	0
1311	Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen.. Blood, 2007, 110, 2832-2832.	1.4	0
1312	Efficacy of Azacytidine (5-AC) Given as Maintenance or Salvage Therapy for Patients (pts) with Acute Leukemia Post Allogeneic Stem Cell Transplantation (HSCT).. Blood, 2007, 110, 3013-3013.	1.4	0
1313	Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) Mutation after Therapy with Tyrosine Kinase Inhibitors (TKIs).. Blood, 2007, 110, 1949-1949.	1.4	0
1314	Salvage Therapy with Standard Dose Cytarabine Is Appropriate for Patients with Acute Myelogenous Leukemia Refractory to Front-Line Therapy with Hypomethylating Agents.. Blood, 2007, 110, 4382-4382.	1.4	0

#	Article	IF	Citations
1315	Kinetics of Bone Marrow Blasts during Remission Induction Course in Acute Myeloid Leukemia: Effect on Complete Remission and Relapse-Free Survival.. Blood, 2007, 110, 1852-1852.	1.4	0
1316	Long-Term Significance of Achieving a Major Cytogenetic Response (MCyR) without a Complete Hematologic Response (CHR) among Patients (pts) with Chronic Myeloid Leukemia (CML) in Advanced Phase Treated with Second Generation Tyrosine Kinase Inhibitors (TKI).. Blood, 2007, 110, 1944-1944.	1.4	0
1317	Genome-Wide Identification of Aberrant Promoter Associated CpG Island Methylation in Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 2127-2127.	1.4	0
1318	Epigenetic Inactivation of Notch Signaling Target Genes HES in B Cell Acute Lymphoblastic Leukemia.. Blood, 2008, 112, 3372-3372.	1.4	0
1319	Outcome of First Salvage Therapy in Core Binding Factor Associated Acute Myelogenous Leukemia Is Less Than Optimal. Blood, 2008, 112, 2952-2952.	1.4	0
1320	The Heterogeneous Prognosis of Patients with Myelodysplastic Syndrome (MDS) and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS?.. Blood, 2008, 112, 1644-1644.	1.4	0
1321	Experience with the Combination of a Hypomethylating Agent and Valproic Acid in Pediatric Acute Myelogenous Leukemia. Blood, 2008, 112, 4036-4036.	1.4	0
1322	Increase in the Incidence of Secondary Acute Myeloid Leukemia (2-AML): A Single Institution Experience Over 20 Years.. Blood, 2008, 112, 1498-1498.	1.4	0
1323	Phase II Study of Thymoglobulin, Cyclosporine and G-CSF for Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome. Blood, 2008, 112, 5080-5080.	1.4	0
1324	Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment.. Blood, 2008, 112, 2078-2078.	1.4	0
1325	Antileukemia Activity of JNJ-26481585, a Potent Second-Generation Histone Deacetylase Inhibitor. Blood, 2008, 112, 2631-2631.	1.4	0
1326	Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy.. Blood, 2008, 112, 2094-2094.	1.4	0
1327	Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies.. Blood, 2008, 112, 2125-2125.	1.4	0
1328	Clinical Parameters in 391 Iron-Overloaded Patients with Lower-Risk MDS Enrolled in a Prospective, Non-Interventional Multicenter Registry.. Blood, 2009, 114, 4834-4834.	1.4	0
1329	Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes.. Blood, 2009, 114, 1248-1248.	1.4	0
1330	A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.. Blood, 2009, 114, 1772-1772.	1.4	0
1331	The Combination of PEITC (Phenehyl Isothiocyanate) with a Histone Deacetylase Inhibitor (HDACi) Has Synergistic Antileukemia Activity by Overcoming a Redox-Mediated Resistance Pathway.. Blood, 2009, 114, 1739-1739.	1.4	0
1332	The Outcome of Patients (pts) with Acute Promyelocytic Leukemia (APL) Who Fail Both Allâ€“Trans-retinoic Acid (ATRA) and Arsenic Trioxide (ATO).. Blood, 2009, 114, 4143-4143.	1.4	0

#	Article	IF	Citations
1333	Clinical Characterization and Proteomic Consequences of Mutated Ras in Acute Myeloid Leukemia.. Blood, 2009, 114, 330-330.	1.4	0
1334	Outcome of Therapy-Related Acute Promyelocytic Leukemia (t-APL) with or without Arsenic Trioxide (ATO) as a Component of Frontline Therapy.. Blood, 2009, 114, 1050-1050.	1.4	0
1335	DNA Methylation and Gene Expression Analysis in a Phase II Randomized Study of Decitabine Vs. Decitabine Plus Valproic Acid in MDS and AML.. Blood, 2009, 114, 3808-3808.	1.4	0
1336	BARD1: a New Target In Leukemia. Blood, 2010, 116, 4642-4642.	1.4	0
1337	Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival. Blood, 2010, 116, 300-300.	1.4	0
1338	Analysis of Regulatory miRNAs of Histone Demethylase JMJD3 In MDS CD34+ Hematoprogenitor Cells. Blood, 2010, 116, 609-609.	1.4	0
1339	Decitabine Is Effective and Safe In Patients with Chronic Myelomonocytic Leukemia. Blood, 2010, 116, 4032-4032.	1.4	0
1340	Prognostic Factors Associated with Progression of Myelodysplastic Syndromes (MDS) to Acute Myeloid Leukemia (AML) In Patients (pts) Treated with Decitabine. Blood, 2010, 116, 4956-4956.	1.4	0
1341	Clinical Characterization, Prognostic Implications, and Response to Therapy In Patients with Myelodysplastic Syndrome (MDS) and Chromsome 17 Abnormality: A Single Institutional Experience. Blood, 2010, 116, 2930-2930.	1.4	0
1342	Seven-Year Follow-up Data on Sequential Prospective Trials of Imatinib 400mg Vs 800mg Daily Schedule for Front-Line Treatment of Chronic Myeloid Leukemia (CML).. Blood, 2010, 116, 3438-3438.	1.4	0
1343	Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy. Blood, 2010, 116, 2936-2936.	1.4	0
1344	Third Party Umbilical Cord Blood Regulatory T Cells Prevents Graft Versus Host Disease In a Xenogenic Murine Model.. Blood, 2010, 116, 3737-3737.	1.4	0
1345	Phase I Study Results of Gimatecan In the Treatment of Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 1883-1883.	1.4	0
1346	Death In Complete Remission Among Patients with Acute Myeloid Leukemia: A Preventable Problem?. Blood, 2010, 116, 2710-2710.	1.4	0
1347	Proteomic Profiling In CD34+CD38- Stem Cells and CD34+ Cells From 185 Myelodysplasia Patients Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurrent Proteins Expression Signatures with Prognostic Implications. Blood, 2010, 116, 2126-2126.	1.4	0
1348	MYBL2 Is a Candidate Tumor Suppressor Gene In MDS. Blood, 2010, 116, 1865-1865.	1.4	0
1349	Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO).. Blood, 2010, 116, 1085-1085.	1.4	0
1350	Cytogenetic Evolution (CE) In Patients (pts) with Low and Intermediate Risk Myelodysplastic Syndromes (MDS) Is Associated with Poor Prognosis. Blood, 2010, 116, 2941-2941.	1.4	0

#	Article	IF	Citations
1351	Levels of Mir-29b or Mir-101 Do Not Predict Response In Patients (pts) with Acute Myelogenous Leukemia (AML) Treated with the Combination of 5-Azacytidine, Valproic Acid and ATRA. Blood, 2010, 116, 1701-1701.	1.4	0
1352	Therapeutic Modalities and New Molecular Targets in MDS. , 2011, , 219-238.		0
1353	Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL,. Blood, 2011, 118, 3902-3902.	1.4	0
1354	Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (TelintraÂ®, TLK199) in Combination with Lenalidomide (RevlimidÂ®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). Blood, 2011, 118, 2778-2778.	1.4	0
1355	Clofarabine Does Not Impact Negatively the Outcomes of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Stem Cell Transplantation and Is Not Associated with Higher Liver Toxicity Rates Compared with Standard Chemotherapy. Blood, 2011, 118, 1489-1489.	1.4	0
1356	Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2011, 118, 1550-1550.	1.4	0
1357	Impact of Epigenetic Therapy Versus Conventional Chemotherapy on Survival of Elderly Patients with Acute Myeloid Leukemia. Blood, 2011, 118, 1494-1494.	1.4	0
1358	AR-67, a DNA Topo-Isomerase I Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase II Trial of Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML),. Blood, 2011, 118, 3820-3820.	1.4	0
1359	Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy. Blood, 2011, 118, 2749-2749.	1.4	0
1360	Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia,. Blood, 2011, 118, 3557-3557.	1.4	0
1361	Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia,. Blood, 2011, 118, 3629-3629.	1.4	0
1362	Phase II Study of the Histone Deacetylase Inhibitor Panabinostat (LBH589) in Patients with Low or Intermediate-1 Risk Myelodysplastic syndrome. Blood, 2011, 118, 1731-1731.	1.4	0
1363	Incidence, Characteristics, and Outcome of FLT3-ITD Mutations in AML Arising from an Antecedent Hematologic Disorder. Blood, 2011, 118, 2522-2522.	1.4	0
1364	Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience. Blood, 2011, 118, 2750-2750.	1.4	0
1365	Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes,. Blood, 2011, 118, 3812-3812.	1.4	0
1366	EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC),. Blood, 2011, 118, 3769-3769.	1.4	0
1367	Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS),. Blood, 2011, 118, 3639-3639.	1.4	0
1368	Patients' Comorbidities and Overall Survival in Primary Myelofibrosis (PMF). Blood, 2011, 118, 5164-5164.	1.4	0

#	Article	IF	Citations
1369	Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR). Blood, 2011, 118, 1530-1530.	1.4	0
1370	Impact of Combining Targeted Agents with High-Dose Cytarabine-Based Induction Chemotherapy on Acute Myeloid Leukemia Outcomes: The M.D. Anderson Cancer Center Experience. Blood, 2011, 118, 1539-1539.	1.4	0
1371	Long Term Results of Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome: Analysis of Prognostic Factors. Blood, 2011, 118, 4531-4531.	1.4	0
1372	Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center. Blood, 2011, 118, 2606-2606.	1.4	0
1373	Clofarabine-Containing Chemotherapy Does Not Increase the Risk of Infectious Complications in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2011, 118, 4256-4256.	1.4	0
1374	ROS Activation Independent From Iron Overload in MDS. Blood, 2011, 118, 2798-2798.	1.4	0
1375	Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML). Blood, 2011, 118, 4443-4443.	1.4	0
1376	Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS),. Blood, 2011, 118, 3802-3802.	1.4	0
1377	Allogeneic Hematopoeitic Stem Cell Transplantation (AHSCT) Versus Hypomethylating Agents (HMA) in Patients (pts) with Myelodysplastic Syndrome (MDS): A Case-Control Study. Blood, 2011, 118, 1707-1707.	1.4	0
1378	Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen. Blood, 2011, 118, 1524-1524.	1.4	0
1379	Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse,. Blood, 2011, 118, 3569-3569.	1.4	0
1380	Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC). Blood, 2011, 118, 981-981.	1.4	0
1381	Outcome of Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy. Blood, 2011, 118, 1518-1518.	1.4	0
1382	Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia.. Blood, 2012, 120, 2587-2587.	1.4	0
1383	Infectious Complications in Patients with Relapsed Acute Myeloid Leukemia (AML) Receiving Clofarabine Versus Fludarabine-Containing Salvage Chemotherapy Regimens. Blood, 2012, 120, 4322-4322.	1.4	0
1384	The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution. Blood, 2012, 120, 1693-1693.	1.4	0
1385	Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML). Blood, 2012, 120, 3797-3797.	1.4	0
1386	Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities. Blood, 2012, 120, 2029-2029.	1.4	0

#	Article	IF	Citations
1387	Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia. Blood, 2012, 120, 3617-3617.	1.4	0
1388	A Prognostic Score System for Survival in Secondary AML: Review of 1073 Patients Observed At MDACC. Blood, 2012, 120, 131-131.	1.4	0
1389	Disparity in Perceptions of Disease, Treatment Effectiveness and Treatment Adherence Between Physicians and Patients with Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 4949-4949.	1.4	0
1390	Low Frequency of Molecular Alterations of H3.3-Atrx-Daxx Chromatin Remodeling Component Genes in Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 3844-3844.	1.4	0
1391	Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen. Blood, 2012, 120, 3609-3609.	1.4	0
1392	Upregulation of Focal Adhesion Kinase, a Potential Therapeutic Target, in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).. Blood, 2012, 120, 2827-2827.	1.4	0
1393	Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).. Blood, 2012, 120, 2623-2623.	1.4	0
1394	A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily Ã— 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS). Blood, 2012, 120, 3851-3851.	1.4	0
1395	Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. Blood, 2012, 120, 1488-1488.	1.4	0
1396	Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (Â± Histone Deacetylase Inhibitors).. Blood, 2012, 120, 2483-2483.	1.4	0
1397	Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis. Blood, 2012, 120, 3802-3802.	1.4	0
1398	Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood, 2012, 120, 3554-3554.	1.4	0
1399	Toll-Like Receptor (TLR) Signaling Adaptor Protein MYD88 in Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 556-556.	1.4	0
1400	Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy. Blood, 2012, 120, 1417-1417.	1.4	0
1401	Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients. Blood, 2012, 120, 3845-3845.	1.4	0
1402	Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 1700-1700.	1.4	0
1403	Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP). Blood, 2012, 120, 4939-4939.	1.4	0
1404	Prognostic Models for Patients with Myelodysplastic Syndromes. , 2013, , 153-167.		0

#	Article	IF	Citations
1405	Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age. Blood, 2013, 122, 1530-1530.	1.4	0
1406	Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA). Blood, 2013, 122, 2801-2801.	1.4	0
1407	Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). Blood, 2013, 122, 1424-1424.	1.4	0
1408	Incidence Of and Risk Factors For Acute Myeloid Leukemia Involvement Of The Central Nervous System. Blood, 2013, 122, 3883-3883.	1.4	0
1409	Fludarabine and Cytarabine Based Induction Therapy Is Associated With High Response Rate and Durable Remission With Low Treatment Related Mortality In Elderly Patients With Core-Binding Factor AML (CBF-AML). Blood, 2013, 122, 3945-3945.	1.4	0
1410	Overexpression Of Mir-125a In Bone Marrow CD34+ cells Of Patients With Myelodysplastic Syndrome Is Correlated To a Poor Prognosis and May Contribute To The Pathogenesis Of The Disease Through The Modulation Of NF-Kb Activation and Enhancement Of Differentiation Arrest. Blood, 2013, 122, 5206-5206.	1.4	0
1411	Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR+) Populations In Patients With Myelodysplastic Syndrome (MDS). Blood, 2013, 122, 5231-5231.	1.4	0
1412	Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years. Blood, 2013, 122, 3886-3886.	1.4	0
1413	Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients. Blood, 2013, 122, 3948-3948.	1.4	0
1414	Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2013, 122, 1451-1451.	1.4	0
1415	Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural History and Clinical Outcome By Therapeutic Approach. Blood, 2013, 122, 2825-2825.	1.4	0
1416	FOXP3 Is a Direct Target Of miR15a/16 in Umbilical Cord Blood Regulatory T Cells. Blood, 2013, 122, 3261-3261.	1.4	0
1417	Clinical Characteristics and Outcomes In Patients With Acute Promyelocytic Leukemia (APL) and Hyperleukocytosis. Blood, 2013, 122, 1343-1343.	1.4	0
1418	Assessment Of EZH2 Expression In CD34+ Bone Marrow Progenitor Cells Of Patients Of Myelodysplastic Syndromes (MDS). Blood, 2013, 122, 2805-2805.	1.4	0
1419	EphB1 Downregulation In Acute Myeloid Leukemia: Suppressing p53-Dependent DNA Damage Control System. Blood, 2013, 122, 2484-2484.	1.4	0
1420	Recurrent Patterns Of Histone Methylation and Acetylation Regulating Protein Expression In Acute Myelogenous Leukemia (AML). Blood, 2013, 122, 3733-3733.	1.4	0
1421	Down-Regulated Expression Of Protection Of Telomeres 1 (POT1) Gene In Bone Marrow Hematopoietic Progenitor Cell Compartment Has Prognostic Value In Myelodysplastic Syndromes (MDS). Blood, 2013, 122, 1511-1511.	1.4	0
1422	Differential Prognostic Impact Of Peripheral Blood Blast Clearance In AML Based On Type Of Therapy and FLT3 Mutation Status. Blood, 2013, 122, 2584-2584.	1.4	0

#	Article	IF	Citations
1423	Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience. Blood, 2014, 124, 2273-2273.	1.4	0
1424	Comparison of Risk Models for Patients with Lower Risk Myelodysplastic Syndromes. Blood, 2014, 124, 1919-1919.	1.4	0
1425	Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes. Blood, 2014, 124, 4658-4658.	1.4	0
1426	Therapy-Related Myeloid Neoplasms in Breast Cancer Patients: A Single-Institution Report of 150 Cases. Blood, 2014, 124, 962-962.	1.4	0
1427	A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood, 2014, 124, 164-164.	1.4	0
1428	Knowledge That the Myelodysplastic Syndromes (MDS) Are a Type of Cancer Does Not Influence Patient Perception of Treatment Discontinuation. Blood, 2014, 124, 6015-6015.	1.4	0
1429	Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2014, 124, 4641-4641.	1.4	0
1430	Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). Blood, 2014, 124, 3259-3259.	1.4	0
1431	Azacytidine and Vorinostat in Patients with Chronic Lymphocytic Leukemia (CLL) Diagnosed with Therapy-Related Myelodysplastic Syndromes/Acute Myeloid Leukemia (t-MDS/AML). Blood, 2014, 124, 5627-5627.	1.4	0
1432	Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up. Blood, 2014, 124, 4664-4664.	1.4	0
1433	A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome. Blood, 2014, 124, 523-523.	1.4	0
1434	The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure. Blood, 2014, 124, 3275-3275.	1.4	0
1435	Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype. Blood, 2014, 124, 3548-3548.	1.4	0
1436	Minimal Residual Disease (MRD) Assessed By Multi-Parameter Flow Cytometry (MFC) Is Highly Predictive of Outcome in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 1079-1079.	1.4	0
1437	Prognostic Factors for Outcome in Patients (pts) with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody. Blood, 2014, 124, 2288-2288.	1.4	0
1438	Frequency and Impact of Molecular Responseâ€™s with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). Blood, 2014, 124, 3156-3156.	1.4	0
1439	Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy. Blood, 2014, 124, 3258-3258.	1.4	0
1440	Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-Î²B Activation. Blood, 2014, 124, 1930-1930.	1.4	0

#	Article	IF	Citations
1441	Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes. Blood, 2014, 124, 4663-4663.	1.4	0
1442	MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes. Blood, 2014, 124, 5334-5334.	1.4	0
1443	The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA). Blood, 2014, 124, 1935-1935.	1.4	0
1444	Retrospective Analysis of Survival in Patients with Acute Erythroid Leukemia (AML-6) Treated with Conventional Chemotherapy Versus Hypomethylating Agents. Blood, 2014, 124, 2278-2278.	1.4	0
1445	A Phase II Feasibility Study of Prophylactic White Cell Transfusions for the Prevention of Infection in AML Patients Undergoing Induction Therapy. Blood, 2014, 124, 1564-1564.	1.4	0
1446	Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications. Blood, 2014, 124, 4631-4631.	1.4	0
1447	Phase I-II Study of Sequential Therapy with Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA regimen) in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 2014, 124, 5283-5283.	1.4	0
1448	Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience. Blood, 2014, 124, 1924-1924.	1.4	0
1449	Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes). Blood, 2014, 124, 1922-1922.	1.4	0
1450	Retrospective Analysis to Correlate Impact of Symptom Burden and Quality of Life to Treatment Outcome with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Chronic Phase. Blood, 2014, 124, 4548-4548.	1.4	0
1451	Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities. Blood, 2015, 126, 1705-1705.	1.4	0
1452	Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study. Blood, 2015, 126, 2496-2496.	1.4	0
1453	Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs). Blood, 2015, 126, 5257-5257.	1.4	0
1454	Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial. Blood, 2015, 126, 2508-2508.	1.4	0
1455	Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD. Blood, 2015, 126, 4874-4874.	1.4	0
1456	Outcome of Patients with T-Cell ALL Post Frontline Therapy Failure. Blood, 2015, 126, 4873-4873.	1.4	0
1457	The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 3771-3771.	1.4	0
1458	Pharmacological Inhibition of Histone Demethylase JMJD3 Reduces Leukemia Cell Survival and Represses Production of the Cytokine CCL2 in MDS/AML. Blood, 2015, 126, 5219-5219.	1.4	0

#	Article	IF	Citations
1459	PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes. Blood, 2015, 126, 5227-5227.	1.4	0
1460	Does the Achievement of MR4.5 Improve the Outcome of Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Front Line Tyrosine Kinase Inhibitors (TKI)?. Blood, 2015, 126, 5158-5158.	1.4	0
1461	IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 4136-4136.	1.4	0
1462	Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival. Blood, 2015, 126, 3722-3722.	1.4	0
1463	Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis. Blood, 2015, 126, 1313-1313.	1.4	0
1464	Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin. Blood, 2015, 126, 3776-3776.	1.4	0
1465	Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial. Blood, 2015, 126, 3720-3720.	1.4	0
1466	Fatigue, Quality of Life and Related Symptoms: Patient Reported Outcomes in Myelodysplastic Syndrome, Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2015, 126, 4456-4456.	1.4	0
1467	A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure. Blood, 2015, 126, 2888-2888.	1.4	0
1468	The Impact of 20q Deletion on Clinical Presentation, Treatment Response and Survival in Patients with Acute Myeloid Leukemia (AML): The University of Texas MD Anderson Cancer Center Experience. Blood, 2015, 126, 1369-1369.	1.4	0
1469	Outcome of Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (ALL) and Isolated Central Nervous System (CNS) Relapse. Blood, 2015, 126, 2503-2503.	1.4	0
1470	Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia. Blood, 2015, 126, 2579-2579.	1.4	0
1471	Ubiquitin Editing of a Spliceosome Auxiliary Factor By TRAF6 Links Chronic TLR Signaling with Hematopoietic Defects and Myelodysplasia. Blood, 2015, 126, 143-143.	1.4	0
1472	ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma. Blood, 2016, 128, 359-359.	1.4	0
1473	Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Acute Myeloid Leukemia. Blood, 2016, 128, 2756-2756.	1.4	0
1474	KIR Gene Haplotype: An Independent Predictor of Clinical Outcome in MDS Patients. Blood, 2016, 128, 4330-4330.	1.4	0
1475	Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-Îºb Activation. Blood, 2016, 128, 3191-3191.	1.4	0
1476	Characteristics and Outcomes of Older Patients with Secondary AML According to Treatment Approach. Blood, 2016, 128, 2788-2788.	1.4	0

#	Article	IF	Citations
1477	Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2016, 128, 1067-1067.	1.4	0
1478	Validation of the 2016 Revision to the World Health Organization (WHO) Classification of Myelodysplastic Syndromes with Diploid Karyotype. Blood, 2016, 128, 4319-4319.	1.4	0
1479	An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML). Blood, 2016, 128, 5433-5433.	1.4	0
1480	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens. Blood, 2016, 128, 2779-2779.	1.4	0
1481	Activity of Hypomethylating Agents in the Treatment of Therapy-Related Myelodysplastic Syndrome. Blood, 2016, 128, 3177-3177.	1.4	0
1482	Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis. Blood, 2016, 128, 3062-3062.	1.4	0
1483	Impact of Driver Mutations in Patients with Lower-Risk Myelodysplastic Syndromes Classified By the MD Anderson Lower-Risk Prognostic Scoring System. Blood, 2016, 128, 4317-4317.	1.4	0
1484	Impact of the Next-Generation Sequencing Panel on Treatment Choice in Patients with Myelodysplastic Syndrome. Blood, 2016, 128, 4340-4340.	1.4	0
1485	Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes (MDS): Are They Two Faces of the Same Coin? a Study on Behalf of the MDS Clinical Research Consortium (MDS CRC). Blood, 2016, 128, 4321-4321.	1.4	0
1486	Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality. Blood, 2016, 128, 1737-1737.	1.4	0
1487	Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response. Blood, 2016, 128, 4324-4324.	1.4	0
1488	Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 3190-3190.	1.4	0
1489	Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen. Blood, 2016, 128, 5194-5194.	1.4	0
1490	Outcomes of Adult Patients with Relapsed/Refractory Burkitt or Burkitt-like Leukemia/Lymphoma. Blood, 2016, 128, 5150-5150.	1.4	0
1491	Prognostic Value of Clonal Evolution at the Time of Diagnosis in Patients with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors. Blood, 2016, 128, 3064-3064.	1.4	0
1492	Patterns of Relapse in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Achieve Complete Molecular Response with Chemotherapy Plus a Tyrosine Kinase Inhibitor. Blood, 2016, 128, 3977-3977.	1.4	0
1493	Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood, 2016, 128, 1224-1224.	1.4	0
1494	Cryptic Philadelphia Chromosome in Newly Diagnosed Chronic Phase CML (CML-CP): Clinical Characteristics and Treatment Outcome after Treatment with 5 TKI Modalities. Blood, 2016, 128, 3082-3082.	1.4	0

#	Article	IF	Citations
1495	A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood, 2016, 128, 4328-4328.	1.4	0
1496	Clonal Hematopoiesis Increases Risk of Therapy-Related Myeloid Neoplasms. Blood, 2016, 128, 38-38.	1.4	0
1497	Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients. Blood, 2016, 128, 597-597.	1.4	0
1498	Clinical Characteristics of Philadelphia Positive T-Cell Lymphoid Leukemias - (de novo and blast phase) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	0
1499	Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients. Blood, 2016, 128, 1220-1220.	1.4	0
1500	Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality. Blood, 2017, 130, 892-892.	1.4	0
1501	Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood, 2018, 132, 1814-1814.	1.4	0
1502	Telomere Damage Maintains Hematopoietic Stem Cells (HSCs) in an Activated Metabolic State, Which Compromises Their Self-Renewal Capability. Blood, 2018, 132, 174-174.	1.4	0
1503	Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. Blood, 2018, 132, 483-483.	1.4	0
1504	Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood, 2018, 132, 3026-3026.	1.4	0
1505	Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs). Blood, 2018, 132, 3976-3976.	1.4	0
1506	Diverse Landscape of TET2 Variants in MDS and AML. Blood, 2018, 132, 1479-1479.	1.4	0
1507	Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers?. Blood, 2018, 132, 3096-3096.	1.4	0
1508	Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. Blood, 2018, 132, 1514-1514.	1.4	0
1509	Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA. Blood, 2018, 132, 3095-3095.	1.4	0
1510	The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2018, 132, 4359-4359.	1.4	0
1511	Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections. Blood, 2018, 132, 2544-2544.	1.4	0
1512	Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKIs. Blood, 2018, 132, 5442-5442.	1.4	0

#	Article	IF	Citations
1513	Distinct Gene Expression Patterns of Minimal Residual Disease (MRD) Cells in High-Risk AML Patients Identified By RNA-Sequencing. Blood, 2018, 132, 2757-2757.	1.4	0
1514	Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Longer-Term Follow-up Demonstrates Poor Outcomes in Patients with Skin-Only Presentation. Blood, 2018, 132, 3980-3980.	1.4	0
1515	Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). Blood, 2018, 132, 2664-2664.	1.4	0
1516	Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS. Blood, 2018, 132, 3103-3103.	1.4	0
1517	Potential Predictors of Induction Failure and Complete Remission Duration in FLT3-ITD Mutated Acute Myeloid Leukemia. Blood, 2018, 132, 3996-3996.	1.4	0
1518	RNA Expression Profile Using Targeted NGS As a Potential Predictor of Early Molecular Response and Relapse in Core-Binding Factor Acute Myeloid Leukemia. Blood, 2018, 132, 5113-5113.	1.4	0
1519	Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2018, 132, 2791-2791.	1.4	0
1520	Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2018, 132, 2695-2695.	1.4	0
1521	Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Blood, 2018, 132, 1820-1820.	1.4	0
1522	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. Blood, 2018, 132, 3978-3978.	1.4	0
1523	Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR). Blood, 2019, 134, 287-287.	1.4	0
1524	Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib. Blood, 2019, 134, 2753-2753.	1.4	0
1525	Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the ConnectÂ® MDS/AML Registry. Blood, 2019, 134, 4747-4747.	1.4	0
1526	ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage. Blood, 2019, 134, 685-685.	1.4	0
1527	The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). Blood, 2019, 134, 3815-3815.	1.4	0
1528	Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome. Blood, 2019, 134, 1720-1720.	1.4	0
1529	Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome. Blood, 2019, 134, 4252-4252.	1.4	0
1530	High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes. Blood, 2019, 134, 5438-5438.	1.4	0

#	Article	IF	Citations
1531	Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2019, 134, 1719-1719.	1.4	0
1532	Comprehensive DNA 5-Hydroxymethylation Landscapes in Myelodysplastic Syndromes (MDS). Blood, 2019, 134, 2996-2996.	1.4	0
1533	Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes. Blood, 2019, 134, 1711-1711.	1.4	0
1534	Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype. Blood, 2019, 134, 3834-3834.	1.4	0
1535	Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy. Blood, 2019, 134, 2641-2641.	1.4	0
1536	Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy. Blood, 2019, 134, 647-647.	1.4	0
1537	Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 512-512.	1.4	0
1538	Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood, 2019, 134, 17-17.	1.4	0
1539	Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet. Blood, 2019, 134, 2930-2930.	1.4	0
1540	A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). Blood, 2019, 134, 4237-4237.	1.4	0
1541	Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3363-3363.	1.4	0
1542	Clinical Outcomes of Patients with Newly Diagnosed Myelodysplastic Syndrome with MLL Aberrations. Blood, 2021, 138, 4673-4673.	1.4	0
1543	Phase II Study of Lower-Intensity Frontline Therapy for Newly Diagnosed Patients with AML Who Are Unfit or Otherwise Not Eligible for Frontline Clinical Trials. Blood, 2021, 138, 4420-4420.	1.4	0
1544	Dr. Elihu H. Estey (1946â€“2021). American Journal of Hematology, 2022, 97, 166-167.	4.1	0
1545	Single-Cell RNA Sequencing Analysis Reveals Mechanisms of Initiation and Progression in Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 2588-2588.	1.4	0
1546	Characteristics and Outcomes of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center, Prospective Analysis. Blood, 2021, 138, 1213-1213.	1.4	0
1547	Inhibition of MDM2 Improves the Therapeutic Effect of Hypomethylating Agents in Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Blood, 2021, 138, 3664-3664.	1.4	0
1548	NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). Blood, 2021, 138, 2287-2287.	1.4	0

#	Article	IF	Citations
1549	Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. Blood, 2021, 138, 2319-2319.	1.4	0
1550	The Transcriptional and Epigenetic Reprogramming of Aged Hematopoietic Stem Cells Drives Myeloid Rewiring in Clonal Hematopoiesis-Associated Cytopenias. Blood, 2021, 138, 3273-3273.	1.4	0
1551	Clinical and Pathological Characteristics of Hypocellular Myelodysplastic Syndrome : A Single-Center Retrospective Study. Blood, 2021, 138, 1527-1527.	1.4	0
1552	Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 1224-1224.	1.4	0
1553	Clinical Characteristics and Outcomes of Patients Diagnosed with Acute Myeloid Leukemia with Expression of CD71. Blood, 2021, 138, 4449-4449.	1.4	0
1554	Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. Blood, 2021, 138, 694-694.	1.4	0
1555	Update on treatments for patients with myelodysplastic syndrome. Clinical Advances in Hematology and Oncology, 2010, 8, 407-9.	0.3	0
1556	Myeloid neoplasms with 8q24/ <scp> MYC </scp> rearrangement are frequently associated with myelodysplasia, complex karyotype, <scp> TP53 </scp> alterations, and inferior survival. British Journal of Haematology, 0, , .	2.5	0